NZ631476B2 - Antigens associated with inflammatory bowel disease - Google Patents
Antigens associated with inflammatory bowel disease Download PDFInfo
- Publication number
- NZ631476B2 NZ631476B2 NZ631476A NZ63147612A NZ631476B2 NZ 631476 B2 NZ631476 B2 NZ 631476B2 NZ 631476 A NZ631476 A NZ 631476A NZ 63147612 A NZ63147612 A NZ 63147612A NZ 631476 B2 NZ631476 B2 NZ 631476B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- kjm
- annotation
- antibody
- domain
- none
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 53
- 108091007172 antigens Proteins 0.000 title claims abstract description 53
- 102000038129 antigens Human genes 0.000 title claims abstract description 53
- 206010021972 Inflammatory bowel disease Diseases 0.000 title claims abstract description 41
- 102000004965 antibodies Human genes 0.000 claims abstract description 215
- 108090001123 antibodies Proteins 0.000 claims abstract description 215
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 80
- 230000037320 fibronectin Effects 0.000 claims abstract description 79
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 60
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract description 49
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract description 49
- 230000003110 anti-inflammatory Effects 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 27
- 230000001506 immunosuppresive Effects 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 102000016359 Fibronectins Human genes 0.000 claims abstract 3
- 241000282414 Homo sapiens Species 0.000 claims description 65
- 206010011401 Crohn's disease Diseases 0.000 claims description 43
- 229940076144 Interleukin-10 Drugs 0.000 claims description 33
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 27
- 201000006704 ulcerative colitis Diseases 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 23
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 206010009887 Colitis Diseases 0.000 claims description 17
- 230000001809 detectable Effects 0.000 claims description 14
- 206010056979 Colitis microscopic Diseases 0.000 claims description 9
- 208000004341 Lymphocytic Colitis Diseases 0.000 claims description 9
- 101700045840 ECT Proteins 0.000 claims description 8
- 210000004602 germ cell Anatomy 0.000 claims description 8
- 208000008609 Collagenous Colitis Diseases 0.000 claims description 6
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 6
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 206010009895 Colitis ischaemic Diseases 0.000 claims description 5
- 201000008243 diversion colitis Diseases 0.000 claims description 5
- 102000012214 Immunoproteins Human genes 0.000 claims description 2
- 108010036650 Immunoproteins Proteins 0.000 claims description 2
- 208000009137 Behcet Syndrome Diseases 0.000 claims 1
- 201000008335 Behcet's disease Diseases 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 102100008658 FN1 Human genes 0.000 description 77
- 210000001072 Colon Anatomy 0.000 description 43
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 39
- 210000004027 cells Anatomy 0.000 description 35
- 108010066985 F8 monoclonal antibody Proteins 0.000 description 31
- 210000001519 tissues Anatomy 0.000 description 30
- 150000002500 ions Chemical class 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 102100002977 CDR1 Human genes 0.000 description 23
- 150000007523 nucleic acids Chemical group 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 22
- 108020004707 nucleic acids Proteins 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 210000002966 Serum Anatomy 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 230000035492 administration Effects 0.000 description 19
- 229920003045 dextran sodium sulfate Polymers 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000035693 Fab Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 102100011198 EDA Human genes 0.000 description 9
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 9
- 101700043375 sing Proteins 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000018358 Immunoglobulins Human genes 0.000 description 8
- 108060003951 Immunoglobulins Proteins 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000002757 inflammatory Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 6
- 101700004761 SCRIB Proteins 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000004807 localization Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 108010045030 monoclonal antibodies Proteins 0.000 description 6
- 102000005614 monoclonal antibodies Human genes 0.000 description 6
- 229960000060 monoclonal antibodies Drugs 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- 210000004369 Blood Anatomy 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 210000004379 Membranes Anatomy 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000003115 biocidal Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241001515965 unidentified phage Species 0.000 description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
- 230000037177 Biodistribution Effects 0.000 description 4
- 210000004204 Blood Vessels Anatomy 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 229920000665 Exon Polymers 0.000 description 4
- 102000002090 Fibronectin type III Human genes 0.000 description 4
- 108050009401 Fibronectin type III Proteins 0.000 description 4
- 210000004408 Hybridomas Anatomy 0.000 description 4
- 210000000987 Immune System Anatomy 0.000 description 4
- 102000004851 Immunoglobulin G Human genes 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 210000001165 Lymph Nodes Anatomy 0.000 description 4
- 108020004999 Messenger RNA Proteins 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M Potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001580 bacterial Effects 0.000 description 4
- 230000000975 bioactive Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001413 cellular Effects 0.000 description 4
- 108091006028 chimera Proteins 0.000 description 4
- 230000000295 complement Effects 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037240 fusion proteins Human genes 0.000 description 4
- 230000002068 genetic Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000000977 initiatory Effects 0.000 description 4
- 229920002106 messenger RNA Polymers 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 230000002285 radioactive Effects 0.000 description 4
- 206010003246 Arthritis Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108010071919 Bispecific Antibodies Proteins 0.000 description 3
- 210000002744 Extracellular Matrix Anatomy 0.000 description 3
- -1 IFN-y Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 241000229754 Iva xanthiifolia Species 0.000 description 3
- 210000002540 Macrophages Anatomy 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 210000000664 Rectum Anatomy 0.000 description 3
- 229940035295 Ting Drugs 0.000 description 3
- 102100019017 VWF Human genes 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 230000003197 catalytic Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000001472 cytotoxic Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000001094 effect on targets Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000001744 histochemical Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000546 pharmaceutic aid Substances 0.000 description 3
- 230000000770 pro-inflamatory Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000001603 reducing Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 229960001134 von Willebrand factor Drugs 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 210000002683 Foot Anatomy 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 101700086956 IFNG Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013264 Interleukin-23 Human genes 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010025650 Malignant melanoma Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 101710040537 TNF Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000112 colonic Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 239000012502 diagnostic product Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 230000003176 fibrotic Effects 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000003278 mimic Effects 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative Effects 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000003322 phosphorimaging Methods 0.000 description 2
- 229920002496 poly(ether sulfone) Polymers 0.000 description 2
- 229920003208 poly(ethylene sulfide) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 230000035533 AUC Effects 0.000 description 1
- 229940094070 Ambien Drugs 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 210000004507 Chromosomes, Artificial Anatomy 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 201000008260 Crohn's colitis Diseases 0.000 description 1
- 108060002063 Cyclotides Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 101700012588 DELE1 Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N Diatrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- WZUVPPKBWHMQCE-VYIIXAMBSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@@]2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-VYIIXAMBSA-N 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102100016020 IFNG Human genes 0.000 description 1
- 101710014535 IGDCC3 Proteins 0.000 description 1
- 108010027440 Immunoconjugates Proteins 0.000 description 1
- 102000018748 Immunoconjugates Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
- 229940100601 Interleukin-6 Drugs 0.000 description 1
- 210000004347 Intestinal Mucosa Anatomy 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 229940044173 Iodine-125 Drugs 0.000 description 1
- QWTDNUCVQCZILF-UHFFFAOYSA-N Isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 102000019298 Lipocalins Human genes 0.000 description 1
- 108050006654 Lipocalins Proteins 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 101700063472 MXRA8 Proteins 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 210000002500 Microbodies Anatomy 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 210000004693 NK cell Anatomy 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N Pyroglutamic acid Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 229940100996 SODIUM BISULFATE Drugs 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M Sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 241000282890 Sus Species 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 230000036201 Tissue concentration Effects 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 101700023306 USP5 Proteins 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 235000010730 Ulex europaeus Nutrition 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 208000007089 Vaccinia Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000002268 Wool Anatomy 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N Zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- FVZCBRTVBSOYMF-UHFFFAOYSA-M [O-]C(=O)C1=CC=CC(N2C(CCC2=O)=O)=C1I Chemical compound [O-]C(=O)C1=CC=CC(N2C(CCC2=O)=O)=C1I FVZCBRTVBSOYMF-UHFFFAOYSA-M 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000002491 angiogenic Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 230000001588 bifunctional Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035510 distribution Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000013080 embryo development ending in birth or egg hatching Effects 0.000 description 1
- 230000013144 embryo development ending in seed dormancy Effects 0.000 description 1
- 201000009273 endometriosis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000008808 fibrosarcoma Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000024949 interleukin-17 production Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000035498 noncompartmental analysis Effects 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000002246 oncogenic Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 229920000023 polynucleotide Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 201000001263 psoriatic arthritis Diseases 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 238000010242 retro-orbital bleeding Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000013533 rum Nutrition 0.000 description 1
- 101700022066 scaf Proteins 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
Abstract
Disclosed is the use of an antibody conjugate for the preparation of a medicament for the treatment of inflammatory bowel disease (IBD) or the delivery of an immunosuppressive or anti-inflammatory molecule to sites of inflammatory bowel disease (IBD) in a patient, wherein the antibody conjugate comprises an antibody, or an antigen-binding fragment thereof, that binds the Extra Domain-A (ED-A) of fibronectin and is conjugated to an immunosuppressive or anti-inflammatory molecule such as IL-10, said antibody comprising a VH domain and a VL domain, wherein the VH domain comprises heavy chain CDR1, CDR2 and CDR3 amino acid sequences comprising the amino acid sequences of SEQ ID NOs: 1(LFT), 2(SGSGGS) and 3(STHLYL), respectively; and the VL domain comprises light chain CDR1, CDR2 and CDR3 amino acid sequences comprising the amino acid sequences of SEQ ID NOs: 4(MPF), 5(GASSRAT) and 6(MRGRPP), respectively. rises an antibody, or an antigen-binding fragment thereof, that binds the Extra Domain-A (ED-A) of fibronectin and is conjugated to an immunosuppressive or anti-inflammatory molecule such as IL-10, said antibody comprising a VH domain and a VL domain, wherein the VH domain comprises heavy chain CDR1, CDR2 and CDR3 amino acid sequences comprising the amino acid sequences of SEQ ID NOs: 1(LFT), 2(SGSGGS) and 3(STHLYL), respectively; and the VL domain comprises light chain CDR1, CDR2 and CDR3 amino acid sequences comprising the amino acid sequences of SEQ ID NOs: 4(MPF), 5(GASSRAT) and 6(MRGRPP), respectively.
Description
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ANTIGENS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE
The present ion relates to the treatment and detection of
inflammatory bowel disease (13D). The ion involves use of
a specific binding member that binds the ED—A isoform of
fibroneCtin, especially a specific g member that binds
domain ED—A of fibroneC':in. The specific binding member may, for
example, be conjugated to an immunosuppressive or anti—
inflammatory molecule, such as interleukin—10.
Background to the invention
Inflammatory Bowel Disease (13D) is a group of inflammatory
conditions that affect colon and small intestine. The major
types of 13D are s disease (CD) and ulcerative s
(UC). 13D pathogenesis is characterized by different angiogenic
regulation contributing to and perpetuating a chronic
inflammatory state in the bowel (Chidlow et al., 2006, Am J
Physiol. Gastroin :est. river Physiol., 29, G5 — G18). s
disease can affec : any part of the gastrointestinal tract,
whereas ulcerative coli:is is typically restricted to the colon
and rectum (Summe :s RW, Tlliott D?, Qadir K, Ucban JF, on
R, Weinstock JV (2003) Am. J. Gastroenool., 98:2034—2041).
Depending on its severity, treatment of ulcerative colitis may
require immunosuppression to control its symptoms and treatment
usually involves the administration of anti—inflammatory
molecules.
13D is known to be terized by upregulation of pro—
inflammatory cytokines, such as IFN—y, IL—6 and IL—12 (e.g. In—
12p70). For example, Crohn’s disease is known to be associated
with excess IL—12/IL—23 and IFN—y/IL—17 produCtion (Strober et
al. (2007), The l of Clinical Investigation, 117(3), 514—
521). Synthesis of IL—12p70 and IL—23 during active Cfohn’s
disease has also been reported (Fuss et al. 2006, Inf'amm. Rowe]
as. 12:9—15).
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
Fibronectin (FN) is a glycoprotein and is widely expressed in a
variety of normal tissues and body fluids. It is a component of
the extracellular matrix (ECM), and plays a role in many
biological processes, incleing cellular adhesion, ar
ion, haemostasis, thrombosis, wound healing, tissue
differentiation and oncogenic transformation.
Different FN isoforms are generated by alternative splicing of
three regions (fiD—A, fiD—R, IIICS) of the primary transcript FN
pre—mRNA, a process that is modulated by nes and
ellular p { (3alza (1988) F_*J RS .ett., 228, 42—44; Carnemolla
(1989) J. Cell 3iol., 106, 1139—1148; Borsi (1990) F_*J RS Lett.
261, 175—178). ectin contains two type—III glolear eXtra—
domains which may undergo alternative splicing: ED—A and ?D—a
(ffrench—Constant (1995) Exp. Cell Res., 22, 261—271, Kaspar et
al. (2006) Int. J. cancer, 118, 1331—1339). The ED—As of moase
fibronectin and human fibronectin are 96.7% identical (only 3
amino acids differ between the two 90 amino acid sequences).
Expression of the ED—A of fibronectin has been reported in tumour
cells and in solid tumours at the mRNA level in breast cancer
(Jacobs et al. (2002) Human Pa :hol, 33, 29—38, Matsumoto et al.
(1999) Jpn. J. Cancer Res., 90, 320—325) and liver cancer (Oyama
et al. (1989) J 3C, 264, 10331—10334, Tavian et al. (1994) Int. J.
Cancer, 56, 820—825) and at the level of isolated protein in
fibrosarcoma, rhabdomyosarcoma and melanoma (Borsi et al. (1987)
J. Cell 3iol., 104, 595—560). Other than cancer, sion of
the ED—A of fibronectin has been repo :ted in toid arthritis
(WO2009/056268). W02010/078950 also :epor :s expression of ED—A
of fib :onectin in endometriosis, psoriasis and psoriatic
arthritis, however histochemical analysis :evealed a very weak to
virtually absent expression of ?D—A in mu] tiple sis and in
ive colitis. Immunohistochemical analyses reported by
3renmoehl et al. (Int. J. cta Dis. (2007) 22:611—623) show
d CD patLents_ at ED—A expre:sion is decreased in infla ‘Qr u\,» i.testinal mucosa
when compared to control mucosa and increased in
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ulcerative colitis. ehl et a1. (2007) also report
ircreased expression :f EDwA and EDwB ms in fibrotic mucosa
of CD patients. Exrression of ED—A and ED—s isoforms in fibrotic
mtcosa is expected as these fibronectin iso orms are known to be
ed in wound lealing. There is no suggestion in Brenmoehl
et al. (2007) that ED—A is expressed during (active) tD,A given
tke decreased expression of ED—A in inflamed intestinal mucosa of
CD patients compared with mucosa derived from control patients.
The use of binding members Wiich bind tne Eb A isoforn of
fibronectin for the ent or diagnosis of IBD is also not
disclosed in this document.
Interleukin—10 (IL—10) is an anti—inflammatory cytokine that
functions as an important regulator of the immune system.
Although IE—10 is known to have many different roles in the
immune syStem, its two major activities e tion of
ne production by macrophages and inhibition of the
accessory funCtions of macrophages during T cell activation
(Abbas A, nichtman A, Pober J., 1994, Cellular and Molecular
Immunology. 2nd Ed. Philadelphia: W.3. rs y). The
effects of these s cause IL—10 to play mainly an anti—
inflammatory role in the immune system. IL—10 was originally
known as the cytokine synthesis inhibiting factor (CSIF), and the
discovery of this prOtein was based on its biological activity
(Delves P, Roitt I (eds), 1998, Encyclopedia of Immunology, 2nd
Ed. San Diego: Academic Press). Because of its well known anti—
inflammatory properties, IL—10 therapy was introduced as a
potential new anti—inflammatory therapy in s disease (CD)
(Fedorak et al., Gastroenterology (2000) 119, 1473—1482.;
Schreiber et al., Gastroenterology (2000) 119, 1461—1472;
Colombel et al., Gut (2001) 49, 42—46).
lah et al. (Pharmacology Reviews, (2003), 55, 245—269)
review the state of the art of Interleukin—10 therapy in a number
of inflammatory diseases. When reviewing chronic inflammatory
‘ijel disease, Asadullah et al. report that several large
lticenter trials were performed, testing multiple IL—10 dosages
in patients with mild/moderate or therapy refractory CD, as well as in patients
undergoing curative ileal or ileocolonic resection to prevent endoscopic erative
occurrence by systemic administration (Fedorak et al., Gastroenterology (2000) 119,
1473-1482.; ber et al., Gastroenterology (2000) 119, 1461-1472; Colombel et al.,
Gut (2001) 49, 42-46.). The data indicate that IL-10 therapy is safe and well tolerated.
However, IL-10 treatment did not result in icantly higher remission rates or clinical
improvement compared with placebo treatment.
Overall the clinical results were found to be unsatisfying and several explanations for
the disappointment with this therapeutic strategy were discussed by Herfarth and
Scholmerich (Gut (2002) 50, 7).
Therefore, there is a need for effective treatments of various IBD .
y of invention
In one aspect, the present ion provides the use of an antibody conjugate for the
preparation of a medicament for the treatment of inflammatory bowel disease (IBD),
wherein the antibody conjugate comprises an dy, or an antigen-binding fragment
thereof, that binds the Extra Domain-A (ED-A) of ectin and is conjugated to an
immunosuppressive or anti-inflammatory molecule, said antibody comprising a VH
domain and a VL domain, wherein the VH domain comprises heavy chain CDR1, CDR2
and CDR3 amino acid sequences comprising the amino acid sequences of SEQ ID NOs: 1,
2 and 3, tively; and the VL domain comprises light chain CDR1, CDR2 and CDR3
amino acid sequences comprising the amino acid sequences of SEQ ID NOs: 4, 5 and 6,
respectively.
The present invention also provides the use of an antibody conjugate for the
preparation of a medicament for the ry of an immunosuppressive or anti-
inflammatory molecule to sites of inflammatory bowel disease (IBD) in a patient,
wherein the antibody conjugate comprises an antibody, or an antigen-binding fragment
thereof, that binds the Extra Domain-A (ED-A) of fibronectin and is conjugated to the
immunosuppressive or anti-inflammatory molecule, said antibody comprising a VH
domain and a VL domain, wherein the VH domain comprises heavy chain CDR1, CDR2
and CDR3 amino acid sequences comprising the amino acid sequences of SEQ ID NOs: 1,
2 and 3, respectively; and the VL domain comprises light chain CDR1, CDR2 and CDR3
amino acid sequences comprising the amino acid ces of SEQ ID NOs: 4, 5 and 6,
respectively.
The t invention also provides the use of an antibody conjugate for the
preparation of a medicament for the treatment of matory bowel disease (IBD),
wherein said antibody conjugate ses the amino acid sequence of SEQ ID NO: 13.
The present invention also provides the use of an antibody conjugate for the
preparation of a medicament for the treatment of inflammatory bowel disease (IBD),
wherein said antibody conjugate consists of the amino acid ce of SEQ ID NO: 13.
The t invention also provides the use of an antibody conjugate for the
preparation of a medicament for the delivery of human IL-10 to sites of inflammatory
bowel disease (IBD) in a patient, wherein said antibody ate comprises the amino
acid sequence of SEQ ID NO: 13.
The present invention also es the use of an antibody conjugate for the
preparation of a medicament for the delivery of human IL-10 to sites of inflammatory
bowel e (IBD) in a patient, wherein said antibody conjugate consists of the amino
acid sequence of SEQ ID NO: 13.
The present inventors have surprisingly found that, an anti-EDA antibody fused to IL-10,
was able (i) to localise selectively at sites of inflamed colon in vivo in IBD diseased mice
and (ii) to decrease the serum levels of certain pro-inflammatory cytokines in the IBD
diseased mice, in particular interferon-gamma, IL-6 and IL-12p70.
Downregulation of flammatory cytokines through administration of an anti-EDA
antibody fused to IL-10 was particularly surprising as Tilg et al. (Gut (2002), 50, 5)
report that treatment of Crohn's disease patients with recombinant human IL-10
induces interferon-gamma. Shibata et al. (J. Immunol., (1998) 161, 4283-4288) also
report that IL-10 enhances NK cell production of INF-gamma but inhibits macrophage
production of IFN-gamma-inducing factors.
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
ed set by kjm
ore, in a first aspect, the invention es a specific
binding member, e.g. an antibody molecule, that binds the Extra
Domain—A (ED—A) isoform of fibroneCtin (A—FN) for use in a method
of treatment of I3D. The invention also provides the use of a
specific binding member, e.g. an antibody molecule, that binds
the Extfa Domain—A (ED—A) isoform of fibroneCtin for the
manufaCture of a medicament for treating I3D. The ion also
provides a method of treating I33 in a patient, the method
comprising administering to a patient a therapeutically effective
amount of a medicament sing a specific binding member which
binds the ED—A isoform of fibronectin. Preferably, the specific
binding member binds the ED—A isoform of human fibronectin.
rThe specific g member, e.g. an antibody molecule, for use
in this first aspect of the invention, may bind the ED—A of
fibronectin.
rThe specific binding member e.g. an antibody le, for use in
this first aspect of the invention, may be conjugated to a
mo'ecu'e that has immunosuppressive or anti—inflammatory
activity, a detectable label, a radioisotope, o: a bioactive
mo'ecu'e, such as a cytokine, a hormone, a therapeutic
radioisotope, a cytotoxic drug. rThe ic binding member may
be conjugated to the bioactive molecule by a cleavable linker.
In a preferred embodiment, the specific binding member, e.g.
antibody molecule, is conjugated to a molecule that has
immunosuppressive or anti—inflammatory activity, such as IL—lO.
I3D, as referred to herein, may aCtive I3D. In particular, the
I3D may be Crohn’s disease (CD), ulcerative colitis (UC),
collagenous s, lymphocytic colitis, ischaemic colitis,
diversion colitis, 3ehcet’s disease or indeterminate colitis.
The I3D may be CD or UC. The I3D may be CD, collagenous colitis,
lymphocytic colitis, mic s, diversion s,
‘Eihcet’s disease or indeterminate s. In one embodiment, the
D is not UC. The I3D may be an I3D which is not typically
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
restricted to inflammation in the colon and the rectum, such as
CD. The 13D may be an 13D which does not affeCt only the lining
of the colon. Preferably, the IBD is CD. The terms CD, UC,
collagenous colitis, lymphocytic colitis, mic colitis,
ion colitis, Behcet’s e and indeterminate colitis, as
used herein, may refer to active CD, active JC, active
collagenous colitis, aCtive lymphocytic colitis, aCtive ischaemic
colitis, aCtive diversion s, active 3ehcet’s disease and
active indeterminate colitis, respeCtively.
In a second aspect, the invention provides a specific binding
member, e.g. an antibody molecule, that binds the ED—A isoform of
fibronectin for use in the delivery to 13D tissue of a le
conjugated to the specific binding member. The invention also
provides the use of a specific g member, e.g. an dy
mo'ecu'e, that binds the ED—A isoform of fibronectin for the
manufacture of a medicament for delivery to 13D tissue of a
mo'ecu'e conjugated to the specific binding member. The
invention also provides a method of delivering a molecule to 13D
tissue in a human or animal, wherein the molecule is conjugated
to a specific binding member which binds the ED—A isoform of
fibronectin to form a conjugate and the method comprises
administering the conjugate to the human or animal. Preferably,
the specific binding member binds the ED—A isoform of human
fibronectin.
rThe specific g member, e.g. an antibody molecule, for use
in this second aspect of the invention, may bind the ED—A of
fibronectin.
The specific binding member e.g. an antibody molecule, for use in
this second aspect of the ion, may be conjugated to a
detectable label, a radioisOtope, or a bioactive le, such
as a cytokine, a hormone, a therapeutic radioisotope or a
cytotoxic drug. The specific binding member may be conjugated to
‘ije bioactive molecule by a cleavable linker.
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
The specific binding member, e.g. dy molecule, is
prefe :ably conjugated to IL-10.
In a thi :d , the invention provides a specific binding
membe A—I e.g. an dy molecule, that binds the ED—A isoform of
fibroneCtin for use i n a method of diagnosis of 133. The
invention also provides use of a specific binding member that
binds the ED—A isoform of fibronectin for the man Jfacture of a
diagnostic product for diagnosing 13D. The invention also
provides a method of detecting or diagnosing 13D in a human or
animal, wherein the method comprises the steps of:
(a) administering to the human or animal a specific
binding member which binds the ED—A domain of
fibronectin, and
(b) determining the presence or absence of the specific
binding member in sites of 13D of the human or animal
body,
wherein localisation of the specific binding member to
site of 13D indicates the presence of 13D.
Preferably, the specific binding member binds the ED—A m of
human fibronectin.
rThe specific binding member, e.g. an antibody molecule, for use
in this third aspect of the invention, may bind the ED—A of
fibroneCtin.
I-The specific binding member e.g. an dy molecule, for use in
this thi :d aspect of the invention, may be conjugated to a
detectable label, or a radioisotope.
In a fourth aspect, the invention es a specific binding
membe : that binds the ED—A isoform of fibronectin for use in a
method 0 imaging 13D . The invention also provides use of
a specific binding member that binds the ED—A isoform of
{fibroneCtin for the manufacture of an imaging agent for imaging
D . The invention also provides a method of detecting or
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
imaging IRD tissue in a human or animal, wherein the method
comprises the steps of:
(a) administering to the human or animal a specific
binding member which binds the ED—A domain of
fibronectin, and
(b) detecting the binding of the specific g member
to 13D tissue in the human or animal body.
Preferably, the specific binding member binds the ED—A isoform of
human fibronectin.
The specific binding member, e.g. an antibody le, for use
in this fourth aspect of the invention, may bind the ED—A of
fibronectin.
The specific binding member e.g. an antibody molecule, for use in
this fourth aspect of the invention, may be conjugated to a
detectable label, or a radioisOtope.
In a fifth aspect, the invention provides a conjugate comprising
a binding member which binds the ED—A isoform, e.g. the ED—A, of
fibroneCtin conjugated to IL—lO, wherein the conjugate has the
sequence shown in SEQ ID NO: 13. This conjugate is ed to
as F8—IulO herein. As the VB and VL s of this conjugate
are lin<ed by means of a 5 amino acid linker (see Figure 13), the
ate is expected to form noncovalent homodimers in solution.
A specific binding member for Jse in the invention may be an
antibody le which binds the ED—A isoform of ectin
and/or the ED—A of fibronectin, wherein the dy comprises
one or more complementarity determining regions (CDRs) of the F8
dy described herein. These sequences are provided below
(see SEQ ID NOs: 1—6). The CD? sequences of the F8 antibody are
also shown in Figure l.
A specific binding member for use in the invention may comprise
{fie or more CDRs as described herein, e.g. a CDR3, and optionally
so a CDRl and CDR2 to form a set of CDRs.
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
Preferably, a specific binding member for use in the invention
comprises a set of H and/or E CDRs of dy the F8 dy
described herein with ten or fewer, e .g. one, two, three, four,
or five, amino acid substitutions within the disclosed set of H
and/or L CDRs.
Substitutions may potentially be made at any residue within the
set of CDRs, and may be within CDRl, CDR2 and/or CDR3.
A specific binding member for use in the invention may comprise
an antibody molecule, e.g. a human antibody molecule. The
specific binding member ly comp :ises an antibody VH and/or
VL domain. VH domains of specific binding members are also
provided for use in the invention. Within each of the VB and VL
domains are complementarity determining regions, (“CDRs"), and
framework regions, (“FRs”). A VH domain comprises a set of
HCDRs, and a VL domain comprises a se t of LCDRs. An antibody
molecule may comprise an antibody VH domain comprising a VH CDRl,
CDR2 and CDR3 and a framework. It may alternatively or also
comprise an antibody VL domain compri sing a VE CDRl, CDR2 and
CD?3 and a framewor<. All VH and VL sequences, CDR sequences,
sets of CDRs and sets of HCDRs and sets of LCDRs disclosed herein
represent embodiments of a specific b inding member fo: use in the
invention. As described herein, a "set of CDRs" comprises CDRl,
CDR2 and CDR3. Thus, a set of HCDRs refers to HCDRl, HCDRZ and
HCDR3, and a set of ECDRs refers to LCDRl, LCDRZ and ECDR3.
Unless otherwise stated, a "set of CDRs" inclees HCDRs and
LCDQS.
A specific binding member for use in the ion may comprise
an antibody VH domain comprising mentarity ining
regions HCDRl, HCDRZ and HCDR3 and a framework, wherein HCDRl is
SEQ ID NO: I, and wherein optionally HCDRZ is SEQ ID NO: 2,
and/or HCDR3 is SEQ ID NO: 3.
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
ed set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
Typically, a VB domain is paired with a VL domain to provide an
antibody n—binding site, although as discussed further
below, a VB or VL domain alone may be used to bind antigen.
ThJS, a specific binding membe: for u se in the invention may
fu :ther comprise an antibody VE domain comp :ising mentarity
determining regions LCDRl, LCDQZ and LCDR3 and a framework,
wherein LCDRl is SEQ ID NO: 4, and n optionally LCDR? is
SEQ ID NO: 5 and/or LCDR3 is SEQ ID NO: 6.
A specific g member for use in the invention may preferably
comprise an antibody mo'ecu'e for the ED—A of fibronectin,
whereir the antibody mo'ecu'e compris es a VB domain and a VL
domain, wherein the VB domain comprises a framework and a set of
complementarity determining regions HCDRI, HCDRZ and HCDR3 and
whereir the VE domain conprises complementarity determining
regions ECDRl, LCDRZ and LCDR3 and a framework, and wherein
{CDRI ras amino acid sequence SEQ ID NO:
{CDRZ ras amino acid sequence SEQ ID NO:
{CDR3 Fas amino acid sequence SEQ ID NO:
ECDRI ras amino acid sequence SEQ ID NO:
ECDRZ ras amino acid sequence SEQ ID NO: ; and
ECDR3 Fas amino acid sequence SEQ ID NO:
One or more CDRs or a set of CDRs of an antibody may be d
into a framework (e.g. than framework) to provide an antibody
molecule for use in the invention. Framework regions may
comprise htman g rmlin g n s gm nt s gu nc s. Thus, the
framework Hay b g :mlin d, wh r by on or more residues within
the framework are changed to match the residues at the equivalent
position ir the most similar human germline framework. A
specific binding member for use in the invention may be an
isolated ar tibody molecule having a VB domain sing a set of
HCDRs in a human germline framework, e.g. DP47. Normally the
specific binding member also has a VL domain comprising a set of
LCDQS, e.g. in a human germline framework. The human germline
‘Ejamework of the VL domain may be DPK22.
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
A VH domain for use in the invention may preferably have amino
acid sequence SEQ ID NO: 7, which is the VH domain of the F8
antibody. A VL domain for use in the invention may preferably
have amino acid sequence SEQ ID NO: 8, which is the VL domain of
the wildtype F8 antibody.
A specific binding member for use in the invention may be or
comprise a single chain Fv (scFv), comprising a VH domain and a
VL domain joined via a peptide linker. The skilled person may
select an appropriate length and sequence of linker, e.g. at
least 5 or at least 10 amino acids in length, up to about 15, up
to about 20 or up to about 25 amino acids in length. The linker
may have the amino acid sequence GGSGG (SEQ ID NO: 9).
The specific binding member may be a diabody, which is a
multivalent or multispecific fragment construCted by gene fusion
(W09 /1380 ; Holliger et al. (1993a), Proc. Natl. Acad. Sci. USA
90 6 11—61 8).
Preferably, the ic binding member is a scFv which forms
(stable) noncovalent homodimers in solution. For example, the F8
antibody and F8—IL10 conjugate described herein bOth comprise an
scFv which is ed to form (stable) alent homodimers in
solution.
A single chain Fv (scFv) may be sed within a mini—
immunoglobulin or small immunoprotein (SIP), e.g. as described in
(Li et al., (1997), n Engineering, 10: 731—736). An SIP
may comprise an scFv molecule fused to the CH4 domain of the
human IgE secretory isoform IgE—S2 (SW—CH4; Batista et al.,
(1996), J. Exp. Med., 184: 2197—205) forming an imeric
mini—imminoglobulin antibody molecule.
Alternatively, a specific binding member for use in the invention
may comprise an n—binding site within a non—antibody
{:jlecule, normally provided by one or more CDRs e.g. a set of
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
ation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
CDRs in a non—antibody protein scaffold. Specific binding
members, including non—antibody and antibody molecules, are
bed in mor d tail ls wh r h r in.
The specific g member for use in the present invention may
be an antibody molecule comprising the VB domain of the F8
antibody shown in SEQ ID NO:7 and/or the VL domain of the F8
antibody shown in SEQ ID NO:8. The specific binding member for
use in the present invention may be an antibody molecule
comprising the sequence shown in SEQ ID NO: 11. The ic
binding member conjugated to IL—lO of the present invention may
se the sequence shown in SEQ ID NO: 13.
A specific binding member for use in the present invention may
also comprise one or more, for example all six, of the CDRs of
anti ED—A antibodies H1, 32, C5, D5, E5, C8, Fl, E7, E8 or G9, or
variants thereof, or the VB and/or VL domains of anti ED—A
antibodies H1, 32, C5, D5, E5, C8, Fl, E7, E8 or G9, or variants
thereof. The CDR sequences and VB and VL domain sequences of
these antibodies are disclosed in WOZOlO/O78950.
A suitable variant for use in the present invention comprises an
antibody antigen binding site comprising a VB domain and a VL
domain of the F8 antibody described herein, wherein the leucine
(L) residue at position 5 of the VB domain shown as SEQ ID NO:7
is substituted with valine (V) and/or the arginine (R) residue at
position 18 of the VL domain shown as SEQ ID NO:8 is substituted
with lysine (K).
These and other aspects of the invention are described in r
detail below.
Brief description of the figures
Figure 1A shows the amino acid sequence of the anti—ED—A F8
antibody heavy chain (VH) (SEQ ID NO: 7). The amino acid
unence of the heavy chain CDRl (SEQ ID NO: I) of anti—ED—A F8
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
antibody is underlined. The amino aci d sequence of the heavy
chain CDR2 (SEQ ID NO: 2) of the anti?ED—A F8 antibody is shown
in italics and underlined. The amino acid sequence of the heavy
chain CDR3 (SEQ ID NO: 3) of D—A antibody F8 is shown in
bold and underlined. Figure 13 shows the amino acid sequence of
the antiéL‘J D—A F8 antibody link r s qu no b tw n th VH and VL
domains (SEQ ID NO: 9). Figure 1C shows the amino acid sequences
of the anti—ED—A F8 antibody light cha in (VL) (SEQ ID NO: 8). The
amino acid sequence of the light chain CDRl (SEQ ID NO: 4) Of the
arti—ED—A F8 antibody is underlined. The amino acid sequence of
tre light chain CDR2 (SEQ ID NO: 5) of the anti—ED—A F8 antibody
is shown in italics and underlined. The amino acid sequence of
tre light chain CDR3 (SEQ ID NO: 6) of D—A F8 antibody is
skown in bold and underlined. Figure lD shows the amino acid
sequence of th lin< r b tw n th F8 antibody and IL—10 when the
artibody is conjugated to IL—lO. Figu _‘
re 1E shows the amino acid
sequence of human IE—IO.
Figure 2 shows the results of a colon diography from I3D
and y mice. Colons were harvested and exposed to a
phosphor—imaging sc:een (Molecular Dynamics) for 24 hours, and
imaging via Storm 860. Lane—l: colon harvested at 6—hr post
injection from Group 0 (healthy mouse) ; : colon harvested
at 6—hr post injection from Group 2 (I 3D mouse);
Lane—3: colon harvested at 24—hr post injection from Group 0
(healthy mouse); Lane—4: colon harvested at 24—hr post injection
Group 2 (I3D mouse).
Figure 3 shows the biodistribution of 125I—F8—IL10 in healthy or
diseased mice. The charts show the biodistribution of 8—
ILlO in healthy and diseased mice 6 hours post—injeCtion (A) 24
hours post—injeCtion (3) and 96 hours post—injection (C). At 96
hours a preferential accumulation of 125I—F8—IElO in the colon and
in the mesenteric lymph nodes (L.N.) of ed mice is visible
as compared to healthy mice. The sequence of the F8—ILlO
{:jnjugate used in these experiments is shown in SEQ ID NO: 13.
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
Figure 4 shows the cytokine levels in mice treated with F8—ILlO.
The above chart represents the cytokine levels in the serum of
healthy mice (water), diseased mice which received no treatment
( % DSS), ed mice which received F8 antibody in Small
Immune PrOtein format (F8SIP), diseased mice which received F8—
ILlO (F8—I410). The cytokine levels (expressed as pg of protein
pe: ml of serum) : port d ar : Int rl ukin 18, (ILl—b),
Inter'eukin l? (I.—l9p70), eron y (IFNV) and Interleukin 6
(1.46) .
Figure 5 shows the cytokine levels in mice treated with F8—ILlO.
The above chart represents the cytokine levels in the serum of
healthy mice (water), diseased mice which ed no treatment
( % DSS), diseased mice which received F8 antibody in Small
Immune PrOtein format (F8SIP), diseased mice which received F8—
ILlO (F8—IulO). The cytokine levels (whos l v ls w r xpr ss d
as pg of p:otein per ml of serum) reported are: nocyte—
derived chemohine (KC), Interleukin 10 (ILlO) and Tumor Necrosis
Factor alpha (TNFa).
Figure 6 shows histochemical analysis of specimens of colon
tissue from ts affected by ulcerative colitis and by
Crohn’s e probed with the F8 antibody in SIP format and the
Von rand faCtor. rThe ng pattern observed with the F8
antibody and the Von Willebrand factor shows that the F8 stains
the newly formed blood s but not the normal blood vessels
in patients affected by ulcerative colitis and Crohn’s disease.
(Von Willebrand factor is routinely used as a marker of normal
vasculature.)
Figure 7 shows histochemical analysis of specimens of colon
tissue of patients affected by tive co'itis and by Crohn’s
disease (right) and of non—affected colons (left). The ng
pattern observed with the F8 antibody shows that the F8 stains
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
ed set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
more intensely the new forming blood vessels in the diseased
colons.
TERMINOLOGY
Fibronectin
Fibronectin is an antigen subject to alternative ng, and a
number of ative isoforms of fibronectin are <nown, as
d scrib d ls wh r h r in. Extra Domain—A (EDA o: ED—A) is also
known as ED, extra type III repeat A (EIIIA) or EDI. The
sequence of human ED—A has been published by <ornblihtt et al.
(1984), NJcleic Acids Res. 12, 5853—5868 and Paolella et al.
(1988), NJcleic Acids Res. 16, 3545—3557. The sequence of human
ED—A is also available on the SwissPrOt database as amino acids
1631—1720 (Fibronectin type—III 12; extra domain 2) of the amino
acid s qu nc d posit d und r acc ssion number P02751. The
sequence of mouse ED—A is available on the SwissProt database as
amino acids 1721—1810 (Fibronectin type—III 13; extra domain 2)
of the amino acid s qu nc d posit d und r acc ssion number
P11276.
The ED—A isoform of fibfoneCtin (A—Ffl) ns the Extra Domain—
A ( L‘J D—A). The sequence 0. the human A—FN can be dedJced from the
corresponding human fibroneCtin precarsor sequence which is
available on the COt database Jnder accession number
P02751. The sequence of the mouse A—FN can be deduced from the
corresponding mouse fibronectin precarsor sequence which is
available on the COt database Jnder accession number
P11276. The A—FN may be the human ED—A isoform of fibronectin.
The ED—A may be the Ext:a Domain—A of human ectin.
ED—A is a 90 amino acid ce which is inserted into
fibronectin (FN) by alternative ng and is located between
domain 11 and 12 of FN (Eorsi et a'., 1987, J. Cell 3iol., 104,
‘EiS—600). ED—A is mainly absent in the plasma form of FN but is
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
abundant during embryogenesis, tissue remodelling, fibrosis,
c transplantation and solid tumour growth.
Alternative splicing
ative splicing refers to the occarrence of different
patterns of splicing of a primary RNA transcript of DNA to
produce different mRNAs. After excision o_ int:ons, selection
may determine which exons are spliced together to form the mRNA.
Alternative splicing leads to production of ent isoforms
containing different exons and/or different numbers of exons.
For example one isoform may comprise an additional amino acid
sequence corresponding to one or more exons, which may se
one or more domains.
Specific binding member
This describes one member of a pair of molecules that bind
ically to one another. The members of a specific binding
pair may be naturally derived or wholly or partially
synthetically produced. One member of the pair of molecules has
an area on its surface, or a cavity, which binds to and is
therefore complementary to a particular spatial and polar
organization of the other member of the pair 0: 'es.
Examples of types of binding pairs are antigen—antibody,
biotin—avidin, hormone—hormone receptor, receptor—ligand,
enzyme—substrate. rThe present invention is concerned with
antigen—antibody type reactions.
A specific binding member ly comprises a molecule having an
antigen—binding site. For example, a specific binding member may
be an antibody molecule or a non—antibody protein that comprises
an antigen—binding site. A specific binding member, as ed
to herein, is preferably an antibody molecule.
‘fj antigen binding site may be provided by means of arrangement
complementarity ining regions (CDRs) on non—antibody
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
ed set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
protein scaffolds chh as fibronectin or cytochrome 3 etc. (Haan
& Maggos, (2004), 3ioCentury, 12(5): Al—A6; Koide et al., (1998),
Journal of Molecula: Biology, 284: 1141—1151; Nygfen et al.,
(1997), Current n in Structural Biology, 7: 463—469), or by
randomising or mu saving amino acid residues of a loop within a
prOtein scaffold to confer binding specificity for a desired
target. Scaffolds for engineering novel binding sites in
proteins have been ed in detail by Nygren et al. (1997)
(Cu :rent Opinion in Structural 3iology, 7: 463—469). Protein
sca Efolds for antibody mimics are sed in WO/0034784, in
which the inventors describe proteins (antibody mimics) that
include a fibronectin type III domain having at least one
randomised loop. A suitable scaffold into which to graft one or
more CDRs, e.g. a set of HCDRs, may be provided by any domain
member of the immunoglobulin gene superfamily. The scaffold may
be a human or non—human protein. An advantage of a non—antibody
protein scaffold is tha c is may provide an n—binding site
in a scaffold molecule that is smaller and/or easier to
manufacture than at i_east some antibody les. Small size of
a binding member may confer useful physiological ties such
as an ability to enter ce' _S, penetrate deep into tissues or
reach cargecs wi whin othe : ures, to bind within protein
cavities of the carge can cigen. tigen binding sites in
non—antibody prOtein scaf folds is ed in Wess, 2004, In:
tury, The Bernstein Report on RioRusiness, 12(42), A1—A7.
rTypical
are ns having a s:able backbone and one or more
variable loops, in which the amino acid sequence of the loop or
loops is specifically or ly muta:ed to create an antigen—
binding site cha c binds the target antigen. Such proteins
include the IgG—binding domains of pro:ein A from S. aureus,
transferrin, tet :anectin, fibronectin (e.g. 10th fibroneCtin type
III domain) and lipocalins. Other app :oaches include synthetic
"Microbodies" ore GmbH), which a :e based on cyclotides —
small proteins having intra—molecular disulphide bonds.
d addition to antibody sequences and/or an antigen—binding site,
specific binding member for use in the present invention may
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
comprise other amino acids, e.g. forming a e or
polypeptide, such as a folded domain, or to impart to the
molecule another finctional characteristic in addition to ability
to bind antigen. 3inding members for use in the invention may
carry a detectable label, or may be conjugated to a toxin, a
molecale that exerts immunosuppressive or nflammatory
effeCt or a targeting moiety or enzyme (e.g. via a peptidyl bond
or ). Preferably, a binding members for use in the
ion is ated to interleukin 10.
For example, a binding member may comprise a catalytic site (e.g.
in an enzyme domain) as well as an antigen binding site, wherein
the n binding site binds to the antigen and thus targets
the catalytic site to the n. The catalytic site may
inhibit biological function of the n, e.g. by cleavage.
Although, as noted, CDRs can be carried by non—antibody
scaffolds, the struCture for carrying a CDR or a set of CDRs will
generally be an antibody heavy or light chain sequence or
substantial portion thereof in which the CDR or set of CDRs is
located at a location corresponding to the CDR or set of CDRs of
naturally ing VH and VL antibody le domains encoded
by rearranged immunoglobulin genes. The structures and locations
of immunoglobulin variable domains may be determined by reference
to Kabat et al. (1987) (Sequences of Proteins of Immunological
Interest. 4th Edition. US Department of Health and Human
Services.), and updates thereof, now available on the Internet
(at immJno.bme.nwu.edu or find “Kabat” using any search engine).
3y CDR region or CDR, it is intended to te the
hypervariable regions of the heavy and light chains of the
immJnog'obu'in as defined by Kabat et al. (1987) Sequences of
ns of Immuno'ogica' Interest, 4th Edition, US Deparomen, of
Health and Human Services (Kabat et al., (l99la), Sequences of
PrOteins of Immuno'ogica' Interest, 5th Edition, US Deparomen, of
{fialth and Human es, PJbliC Service, NIH, Washington, and
ter ns). An antibody typically contains 3 heavy chain
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
CDRs and 3 light chain CDRs. The term CDR or CDRs is used here in
order to indicate, according to the case, one of these regions or
several, or even the whole, of these regions which contain the
majority of the amino acid residJes sible for the binding
by affinity of the antibody for the antigen or the epitope which
it recognizes.
Among the six short CDR sequences, the thi:d CD? of the heavy
chain (HCDR3) has a greater size variability (greater diversity
essentially due to the mechanisms of arrangement 0. the genes
which give rise to it). It can be as short as 2 amino acids
although the t size known is 26. Functionally, HCDR3 plays
a role in part in the determination of the icity of the
antibody (Segal et al., (1974), PNAS, 71:4298—4302; Amit et al.,
(1986), e, 233:747—753; Chothia et al., (1987), J. Mol.
3iol., 196:901—917; Chothia et al., (1989), Nature, 342:877—883;
Caton et al., (1990), J. Immunol., 144:1965—1968; Sharon et al.,
(1990a), PNAS, 87:4814—4817; Sharon et al., (1990b), J. Immunol.,
144:4863—4869; Kabat et al., (1991b), J. l., 147:1709—
1719).
Antibody Molecule
This describes an immunoglobulin whethe: l or partly or
wholly synthetically produced. The term also relates to any
polypeptide or protein comprising an antibody antigen—binding
site. It must be understood here that the invention does not
relate to the dies in natural form, that is to say they are
not in cheir natural nment bit that they have been able to
be isolated or obtained by purification from natural sources, or
else obtained by genetic recombination, or by chemical synthesis,
and that they can then contain unnatural amino acids as will be
described later. Antibody fragments that comprise an antibody
antigen—binding site e, but are not limited to, dy
molecules such as Fab, Fab’, Fab’—SH, scFv, Fv, dAb, Pd; and
diabodies.
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
It is possible to take monoclonal and other antibodies and use
techniques of recombinant DNA technology to produce Other
antibodies or chimeric molecules that bind the target antigen.
Such techniques may involve introducing DNA encoding the
immunoglobulin variable region, or the CDRs, of an antibody to
the constant regions, or constant regions plus framework regions,
of a ent immunoglobulin. See, for instance, EP—A—184187,
G3 2188638A or EP—A—239400, and a large body of uent
literacure. A hybridoma or other cell producing an antibody may
be subject to genetic mutation or other changes, which may or may
not alter the binding specificity of antibodies proched.
As antibodies can be modified in a number of ways, tre term
"antibody molecule" should be construed as ng any binding
member or substance having an antibody antigen—bindirg site with
the required specificity and/or binding to antigen. Thus, this
term covers antibody fragments and derivatives, incltding any
polypeptide comprising an dy antigen—binding site, r
natural or wholly or partially synthetic. Chimeric Holecules
sing an antibody antigen—binding site, or equivalent, fused
to r polypeptide (e.g. d from another species or
belonging to anOther antibody class or subclass) are therefore
included. Cloning and expression of chimeric antibodies are
described in EP—A—0120694 and EP—A—0125023, and a large body of
subsequent literature.
Further techniques available in the art of antibody engineering
have made it possible to isolate human and humanised antibodies.
For e, human hybridomas can be made as described by
Kontermann & Dubel (2001), S, Antibody Engineering, Springer—
Verlag New York, LLC; ISBN: 3545. Phage display, r
established technique for generating binding members has been
described in detail in many publications such as WO92/01047
(discussed further below) and US patents US5969108, US5565332,
US5733743, US5858657, US5871907, US5872215, 793, US5962255,
‘Eid Kontermann6140471, US6172197, US6225447, US6291650, US6492160, US6521404
& Dubel (2001), S, Antibody Engineering, Springer—
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
Ver:_ag New York, LLC; ISBN: 3540413545. E‘ransgenic mice in which
the mouse antibody genes are vated and onally
rep:_aced with human antibody genes while I_eaving intact other
components of the mouse immune system, can be used for isolating
human antibodies (Mendez et al., (1997), Nature Genet, 15(2):
Synthetic dy molecules may be created by expression from
genes ted by means of oligonucleotides sized and
assembled within suitable expression veCtors, for example as
described by Knappik et al. (2000) J. Mol. Biol. 296, 57—86 or
Krebs et al. (2001) Journal of Immunological Methods, 254 67—84.
It has been shown that fragments of a whole antibody can perform
the funCtion of binding antigens. Examples of binding fragments
are (i) the Fab fragment consisting of VL, VH, CL and CH1
domains; (ii) the Fd fragment consisting of the VH and CH1
domains; (iii) the Fv f:agment consisting of the V4 and VH
domains of a single antibody; (iv) the dAb fragment (Ward et al.
(1989) Nature 341, 544—546; McCaffecty et al., (1990) Nature,
348, 552—554; Holt et al. (2003) Trends in Biotechnology 21, 484—
490), which consists of a VH or a V4 domain; (v) isolated CDR
regions; (vi) F(ab')2 fragments, a bivalent nt comprising
two linked Fab fragments (vii) single chain Fv molecules (scFv),
wherein a VH domain and a VL domain are linked by a peptide
lin<er which allows the two domains to associate to form an
antigen binding site (Rird et al. (1988) e, 242, 423—426;
Huston et al. (1988) PNAS USA, 85, 5879—5883); (viii) ific
single chain Fv dimers (PCT/US92/09965) and (ix) "diabodies",
multivalent or multispecific fragments constructed by gene fusion
(W09 /1380 ; er et al. ), Proc. Natl. Acad. Sci. USA
90 6 11—61 8). Fv, scFv o: diabody molecules may be stabilized
by tr e incorporation of disulphide bridges linking the VH and VL
domains (Reiter et al. (1996), Nature 3iotech, 14, 1239—1245).
Minibodies comprising a scFv joined to a CH3 domain may also be
‘fide (Hu et al. (1996), Cancer Res., 56(13):3055—61). Other
amples of binding fragments are Fab’, which differs from Fab
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
fragments by the addition of a few residues at the carboxyl
terminus of 'he heavy chain CH1 , including one or more
cysteines from the antibody hinge region, and Fab’—SH, which is a
Fab’ fragment in which the cysteine residue(s) of the constant
domains bear a free thiol group.
Antibody fragments for use in the invention can be obtained
starting from any of the antibody mol cul s d scrib d h r in,
e.g. antibody molecules comprising VH and/or VL domains or CDRs
of any of antibodies described herein, by methods such as
ion by enzymes, such as pepsin or papain and/or by cleavage
of the ide bridges by al reduction. In another
manner, antibody fragments of the t ion may be
obtained by technigues of genetic recombination likewise weli
known to the person skilled in the art or else by peptide
synthesis by means of, for example, automatic e
synthesizers such as those supplied by the company Applied
3iosystems, e tc., or by nucleic acid synthesis and expression.
Functional an ibody fragments according to the present invention
include any f inctional fragment whose half—life is increased by a
chemical modi fication, especially by PEGylation, or by
oration in a liposome.
A dAb (domain antibody) is a small monomeric antigen—binding
fragment of an antibody, namely the variable region of an
dy heavy or light chain (Holt et al. (2003) Trends in
Biotechnology 21, 484—490). VH dAbs occur naturally in ds
(e.g. camel, llama) and may be produced by immunizing a camelid
with a target antigen, isolating antigen—specific 3 cells and
direct'y c'on ing dAb genes from individual 3 cells. dAbs are
also producib e in ce'l cu'tJre. Their small size, good
so'ubi'ity and temperature stability makes them particularly
physio'ogicai y useful and sJitable for selection and affinity
maturation. A binding member of the present ion may be a
fib comprising a VB 0: VL domain substantially as set out herein,
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
or a VB or VL domain comprising a set of CDRs ntially as
set out herein.
As used herein, the phrase "substantia"y as set out" refers to
the characteristic(s) of the relevant CDRs of the VB or VL domain
of binding m mb rs d scrib d h r in wi" be either identical or
highly similar to the specified regions of which the sequence is
set out . As described , the phrase "highly similar"
with respect to specified region(s) of one or more variable
domains, it is contemplated that from 1 to about 5, e.g. from 1
to 4, ing 1 to 3, or 1 or 2, or 3 or 4, amino acid
substitutions may be made in the CDR and/or VH or VL domain.
3ispecific or tional antibodies form a second generation of
monoclonal antibodies in which two different le regions are
combined in the same molecule (Holliger and Bohlen 1999 Cancer
and metastasis rev. 18: 411—419). Their use has been
demonstrated both in the stic field and in the therapy
field from their capacity to recruit new effector functions or to
target several molecules on the surface of tumor cells. Where
bispecific antibodi s ar to b us d, th s may be conventional
bispecific antibodies, which can be manufaCtured in a variety of
ways (Hollige: et al. (1993b), Current Opinion 3iotechnol 4, 446—
449), e.g. prepared chemically or from hybrid hybridomas, or may
be any of the bispecific antibody fragments mentioned above.
These antibodies can be obtained by chemical methods (Glennie et
al., (1987) J. l. 139, 2367—2375; Repp et al., (1995) J.
Hemat. 377—382) or somatic methods (Staerz U. D. and 3evan M. J.
(1986) PNAS 83; Suresh et al. (1986) Method. Enzymol. 121: 210—
228) but lik wis by g n tic ngin ring techniques which allow
the heterodimerization to be forced and thus facilitate the
s of erification of the antibody sought (Merchand et al.,
1998 Nature 3iotech. 16:677—681). Examples of bispecific
antibodies include those of the RiT?““technology in which the
binding domains of two antibodies with different specificity can
{ii used and directly linked via short f'exib'e peptides. This
mbines two antibodies on a short sing'e po'ypeptide chain.
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
Diabodies and scFv can be constructed without an Fc region, using
only le domains, ially reducing the effects of anti—
pic reaction.
Bispecific antibodies can be constructed as entire IgG, as
bispecific Fab'2, as Fab'PEG, as diabodies or else as bispecific
scFv. Further, two bispecific dies can be linked using
routine methods known in the art to form tetravalent dies.
Bispecific diabodies, as opposed to bispecific whole antibodies,
may also be particularly useful because they can be readily
constructed and expressed in E.coli. Diabodies (and many other
polypeptides such as antibody fragments) of appropriate binding
specificities can be readily selected using phage display
(WO94/13804) from libraries. If one arm of the diabody is to be
kept constant, for instance, with a icity directed against
a target n, then a library can b mad wh r th oth r arm
is varied and an antibody of riate specificity selected.
Rispecific whole antibodies may be made by ative
engineering methods as described in Ridgeway et al. (1996),
Protein Lng.,_‘ 9, 616—621.
Various methods are available in the art for ing antibodies
t a target antigen. The antibodies may be monoclonal
antibodies, especially of human, murine, chimeric or humanized
origin, which can be obtained according to the standard s
well known to the person skilled in the art.
In general, for the preparation of monoclonal dies or their
functional fragments, especially of murine origin, it is possible
to refer to techniques which are described in particalar in the
manual "Antibodies" (Harlow and Lane, Antibodies: A uaboratocy
Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor N.Y.,
pp. 726, 1988) or to the technique of preparation from hybridomas
described by Kohler and Milstein, 1975, Nature, 256:495—497.
[Annotation] kjm
None set by kjm
ation] kjm
ionNone set by kjm
[Annotation] kjm
ed set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
ed set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
Monoc'ona' antibodies can be obtained, for example, from an
anima' ce'l immunized against A—FN, or one of its fragments
containing the epitope recognized by said monoclonal antibodies,
e.g. a fragment comprising or consisting of ED—A, or a peptide
fragment of ED—A. The A—FN, or one of their fragments, can
especially be produced ing to the usual working methods, by
genetic ination starting with a nucleic acid sequence
contained in the cDNA sequence coding for A—FN, or fragment
thereof, by peptide sis starting from a ce of amino
acids comprised in the peptide sequence of the A—FN and/or
fragment thereof.
Monoclonal antibodies can, for example, be purified on an
affinity column on which A—FN, or one of their fragments
containing the epitope recognized by said monoclonal antibodies,
e.g. a fragment comprising or ting of ED—A, o: a peptide
nt of ED—A, has previously been immobilized. Monoclonal
antibodies can be purified by chromatography on n A and/or
G, followed or not followed by ion—exchange chromatography aimed
at eliminating the residual protein contaminants as well as the
DNA and the LPS, in itself, fo'lowed or not followed by exclusion
chromatography on Sepharose gel in order to eliminate the
potential aggregates due to the presence of dimers or of other
multimers. The whole of these techniques may be used
simultaneously or successively.
Antigen-binding site
This describes the part of a molecule that binds to and is
complementary to all or part of the target ancigen. In an
antibody molecule it is referred to as the antibody antigen—
binding site, and comprises the part of the antibody that binds
to and is complementary to all or part of the target antigen.
Where an antigen is large, an antibody may only bind to a
particular pare of the antigen, which part is termed an e.
An antibody antigen—binding site may be provided by one or more
Dtibody variable domains. An antibody antigen—binding site may
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
ed set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
comprise an antibody light chain variable region (VL) and an
dy heavy chain variable region (VH).
Isolated
This refers to the state in which ic binding members for
use in the invention or c acid encoding such specific
g members, will generally be in ance with the present
invention. Thus, specific binding members, VH and/or VL s
of the present invention may be provided isolated and/or
purified, e.g. from their natural environment, in ntially
pure or homogeneous form, or, in the case of nJcleic acid, free
or substantially free of nucleic acid or genes of origin other
than the sequence encoding a polypeptide with the required
function. Isolated members and isolated nucleic acid will be
free or substantially free of material with which they are
naturally associated such as other polypeptides or nucleic acids
with which they are found in treir natural environment, or the
environment in which th y ar pr par d ( .g. c 11 Cilture) when
such preparation is by recombirant DNA technology practised in
vitro or in vivo. Specific birding members and nucleic acid may
be formulated with diluents or adjuvants and still for practical
purposes be isolated — for example the s will normally be
mixed with gelatin or other carriers if used to coat microtitre
plates for use in immunoassays, or will be mixed with
pharmaceutically acceptable carriers or diluents when used in
diagnosis or therapy. Specific binding members may be
glycosylated, either naturally or by systems of heterologous
eukaryotic cells (e.g. CHO or NSO (ECACC 85110503) cells, or they
may be (for example if produced by expression in a prokaryotic
cell) unglycosylated.
Heterogeneous ations sing antibody molecules may also
be used in the invention. For example, such preparations may be
mixtures of antibodies with full—length heavy chains and heavy
chains lacking the C—terminal lysine, with various degrees of
Dycosylation and/or with derivatized amino acids, such as
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
cyclization of an N—terminal glutamic acid to form a pyroglutamic
acid residue.
One or more specific binding members for an antigen, e.g. the A—
FN, the ED—A of fibronectin, may be obtained by bringing into
contact a library of specific binding members according to the
invention and the antigen or a fragment f, e .g. a fragment
sing or consisting of ED—A, or a peptide fragment of ED—A
and ing one or more specific binding members of the library
able to bind the n.
An antibody library may be screened using Iterative Colony Filter
Screening (ICFS). In ICFS, bacteria containing the DNA ng
l binding specificities are grown in a liquid medium and,
onc th stag of xpon ntial growth has been reached, some
billions 0: them are distributed onto a growth support consisting
of a suitably pr —tr at d m mbran Eilt r which is incubated
urtil completely confluent bacteria; colonies . A second
trap substrate consists of anOth r m mbran filt r, pr —
htmidified and covered with the d antigen.
Tre trap membrane filter is then placed onto a plate containing a
stitable e medium and covered with the growth filter with
tre surface covered with baCterial colonies pointing upwards.
Tre sandwich thus ed is incubated at room temperature for
about 16 h. It is thJS possible to obtain the expression of the
genes encoding antibody fragments scFv having a spreading action,
so that those fragments binding specifically with the antigen
which is present on the trap membrane are trapped. The trap
membrane is then treated to point out bound antibody fragments
scFv with colorimetric techniques commonly used to this purpose.
The position of the coloured spots on the trap fil:er allows one
to go back to the corresponding bacterial colonies which are
t on the growth membrane and produced the an tibody
‘Ejagments trapped. Such colonies are gathered and grown and the
cteria—a few millions of them are distributed on cO a new
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
culture membrane repeating th proc dur s d scrib d above.
Analogoas cycles are then carried out until the ve s
on the trap membrane correspond to single positive co'onies, each
of which represents a potential source of monoclonal dy
fragments directed against the antigen used in the ion.
ICFS is described in e.g. W00246455.
A library may also be displayed on particles or molecular
complexes, e.g. replicable genetic packages such bacteriophage
(e.g. rf7) particles, or other in Vitro display systems, each
le or molecular complex containing nucleic acid encoding
the antibody VH variable domain displayed on it, and optionally
also a displayed V4 domain if present. Phage display is
described in WO92/01047 and e.g. US patents USS969108, US$565332,
743, USS858657, 907, USS872215, USS885793, USS962255,
US6140-7l, US6172197, US6225447, 650, US6492160 and
US6521-04.
Following selection of binding members able to bind the antigen
and yed on bacteriophage or other library particles or
molecular complexes, nucleic acid may be taken from a
bacteriophage or other particle or molecular complex displaying a
said selected binding member. Such nucleic acid may be used in
subsequent production of a binding member or an antibody VH or VL
variable domain by expression from nucleic acid with the sequence
of nucleic acid taken from a bacteriophage or other particle or
molecular complex displaying a said selected binding member.
An antibody VH variable domain with the amino acid ce of an
antibody VH variable domain of a said selected binding member may
be provided in isolated form, as may a binding member comprising
such a VB domain.
Ability to bind the A—FN, or the ED—A of fibronectin, or other
target antigen or isoform may be further tested, e.g. ability to
‘Ejmpete with anti—ED—A antibody F8 for g to the A—FN or a
agment of the A—FN, e.g. the ED—A of fibronectin.
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
A specific binding member for use in the ion may bind the
A—FN and/or the ED—A of fibronectin specifically. A specific
binding member of the present invention may bind the A—FW and/or
the ED—A of fibronectin, with the same affinity as anti—ED—A
antibody F8 e.g. in scFv format, or with an affinity that is
better. A specific binding member for use in the invention may
bind the A—FN and/or the ED—A of fibronectin, with a {D of 3 x
'8 M or an affinity that is better. Preferably, a specific
binding member for use in the ion binds the A—FW and/or the
ED—A of fibronectin, with a KB of 2 x 10'8 M or an affinity that
is better. More preferably, a specific g member for use in
the invention binds the A—FN and/or the ED—A of fibroneCtin, with
a KB of 1.7 x 10'8 M or an affinity that is better. Yet more
preferably, a specific g member for use in the invention
binds the A—FN and/or the ED—A of fibronectin, with a KB of 1.4 x
'8 M or an affinity that is better. Most preferably, a
specific binding member for use in the invention binds the A—FN
and/or the ED—A of fibronectin, with a KB of 3 x 10'9 M or an
affinity that is better.
A specific binding member of the present ion may bind to
the same e on A—FN and/or the ED—A of fibronectin anti—ED—A
antibody F8.
A specific binding member for use in the invention may not show
any significant binding to molecules other than to the A—FN
and/or the ED—A of fibronectin. In particular, the specific
g member may not bind other isoforms of fibronectin, for
example the ?D—R isoform and/or the IIICS isoform of fibronectin.
Variants of antibody molecules disclosed herein may be produced
and used in the present invention. The techniques ed to
make substitutions within amino acid sequences of CDRs, antibody
VH or VL domains, in particular the ork regions of the VH
and VL s, and binding members generally are available in
{:ie art. t sequences may be made, with substitutions that
y or may not be predicted to have a minimal or beneficial
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
effect on activity, and tested for ability to bind A—FN and/or
the ED—A of ectin, and/or for any other desired property.
Variable domain amino acid sequence variants of any of the VB and
VL s whose sequences are specifically disclosed herein may
be employed in accordance with the present invention, as
discussed. Particular variants may include one or more amino
acid sequence alterations (addition, dele tion, substitution
and/or inse :tion of an amino acid residue), may be less than
about 20 alterations, less than about 15 alterations, less than
about 10 alterations or less than about 5 tions, maybe 5,
4, 3, 2 or 1. Alterations may be made in one or more framework
regions and/or one or more CDRs. The al terations normally do not
result in loss of function, so a specific binding member
comprising a thus—altered amino acid seq Jence may retain an
ability to bind A—FN and/or the ED—A of ectin. For
example, it may retain the same quantita :ive binding as a
speci Eic binding member in which the alteration is not made, e.g.
as measured in an assay described herein. The specific binding
membe : comprising a thus—altered amino acid sequence may have an
improved ability to bind A—FN and/or the ED—A of fibronectin.
For example, a specific binding member that binds the ED—A
isoform 0.A ED—A of fibronectin, as referred to herein, may
comprise the V4 domain shown in SEQ ID NO: 7 and the VE domain
shown in SEQ ID NO:8 with 10 or fewer, for example, 5, 4, 3, 2 or
1 amino acid ststitution within the framework region of the VH
and/or VL domain. Such a specific binding member may bind the
ED—A isoform 0 A ED—A of ectin with the same or
ntially the same, ty as a specific binding member
comprising the V 4 domain shown in SEQ ID NO: 7 and the VL domain
shown in SEQ ID VO:8 or may bind the ED—A isoform 0: ED—A of
fibronectin with a higher affinity than a specific binding member
comprising the V { domain shown in SEQ ID NO: 7 and the VL domain
shown in SEQ ID “0:8.
{Eavel VH or VL regions carrying CDR—derived sequences for use in
e invention may be generated using random mutagenesis of one or
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
mo :e selected VH and/or VL genes to generate mutations within the
entire va :iable domain. In some embodiments one or two amino
acid substitutions are made within an entice variable domain or
se t of CDRs. r method that may be used is to direct
mutagenesis to CDR regions of VH or VL genes.
AS noted above, a C DR amino acid sequence substantially as set
out herein may be carried as a CDR in a human dy variable
domain or a substan:ial portion thereof. The HCDR3 sequences
substantially as se: out herein ent embodiments of the
present invention and for example each of these may be carried as
a HCDR3 in a human heavy chain variable domain or a substantial
po :tion thereof.
Va :iable domains employed in the invention may be ed or
de :ived from any germ—line or rear :anged human variable domain,
or may be a synthetic variable domain based on consensus or
actual sequences of known human va :iable domains. A variable
domain can be derived from a non—than antibody. A CDR sequence
fo 5 use in the invention (e.g. CDR3) may be introduced into a
repertoire of variable domains lac<ing a CDR (e.g. CDR3), using
recombinant DNA technology. For example, Marks et al. (1992)
describe methods of producing repe :toires of antibody variable
domains in which sus primers directed at or adjacent to the
5 V end of the variable domain area are used in conjunction with
consensus primers to the third framework region of human VH genes
to provide a repertoire of VH variable domains lacking a CDR3.
Marks et al. further describe how this repertoire may be combined
with a CDR3 of a particular antibody. Using analogous
techniques, the CDR3—derived sequences of the present invention
may be sh Jffled with repertoires of VH or VL domains lacking a
CDR3, and the shuffled complete VH or VL s combined with a
cognate V4 0: VB domain to provide binding members for use in the
ion. rThe repertoire may then be yed in a suitable
host system such as the phage display system of 1047, or
{3yI] of a uent large body of literature, including Kay,
te: & McCafferty (1996), so that le binding members may
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
be seleCted. A repertoire may consist of from anything from 104
individual s upwards, for e at least 105, at least
106, at least 107, at least 108, at least 109 or at least 1010
members.
Similarly, one or more, or all three CDRs may be grafted into a
repertoire of VH or VL domains that are then screened for a
binding member or g membe :s for the A—FN and/or the ED—A of
fibronectin.
One or more of the HCDRl, HCDRZ and HCDR3 of antibody F8 or the
se t of HCDRs of antibody F8 may be employed, and/or one or more
of the LCDRl, LCDR2 and LCDR3 of antibody F8 the set of LCDRs of
antibody F8 may be employed.
Similarly, other VH and VL s, sets of CDRs and sets of
HCDRs and/or sets of LCDRs disclosed herein may be employed.
The A—FN and/or the ED—A of fibroneCtin may be used in a screen
for specific binding members, e.g. antibody les, for use in
the preparation of a medicament for the treatment of 13D. The
screen may a screen Of a reper:oire as disclosed e:_sewhere
herein.
A substantial_ portion of an immunoglobulin va :iable domain may
comprise at least the three CDR regions, together with their
intervening framework s. The portion may also include at
least about 50% of either 0 : both of the first and fourth
framework regions, the 50% terminal 50% of the first
framework region and she N— terminal 50% of the fourth f :amework
region. Additional es at the N—terminal or C—terminal end
of the substantial pa: t of the le domain may be those not
normally associated wi wh na turally occurring variable domain
regions. For example, COHStruction of specific binding members
of the t invention made by recombinant DNA techniques may
:3sult in the introduCtion of N— or C—terminal residues encoded
linkers introduced to facilitate cloning or other manipulation
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
ed set by kjm
steps. Other manipulation steps include the introduction of
linkers to join variable domains disclosed elsewhere herein to
f thher protein sequences including antibody constant regions,
Other variable domains (for example in the produCtion of
diabodies) or detectable/functional labels as discussed in more
d tail ls wh r h r in.
Although specific binding members may comprise a pair of VH and
VL domains, single binding domains based on either VH or VL
domain sequences may also be used in the invention. It is known
that single immunoglobulin domains, especially VH domains, are
capable of g target antigens in a specific manner. For
e, see the discussion of dAbs above.
In the case of eithe: of the single binding s, these
domains may be used to screen for complementary s capable
of g a two—domain binding member able to bind A—FN and/or
the ED—A of fibronectin. This may be achieved by phage display
screening methods using the so—called hierarchical dual
combinatorial approach as disclosed in WO92/01047, in which an
individual colony containing either an H or L chain clone is used
to infect a complete library of clones encoding the other chain
(L or H) and the resulting two—chain binding member is ed
in ance with phage y techniques such as those
described in that reference. This technique is also disc'osed in
Marks 1992.
Specific binding s for use in the present invention may
further comprise antibody nt regions or parts thereof, e.g.
human antibody constant regions or parts thereof. For example, a
VL domain may be ed at its C—cerminal end to antibody light
chain conscanc domains including human CK or Ck chains, e.g. Ck.
Similarly, a specific binding membe: based on a VH domain may be
attached at its C—cerminal end to all or part (e.g. a CHl domain)
of an immunoglobulin heavy chain derived from any antibody
dotype, e.g. IgG, IgA, IgE and IgM and any of the isotype sub—
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
ed set by kjm
classes, particularly IgG1 and IgG4. Any synthetic or other
constant region variant that has these properties and stabilizes
variable regions is also useful in embodiments of the present
invention.
Specific binding members for use in the invention may be labelled
with a detectable or functiona' label. A 'abel can be any
molecule that produces or can be induced to produce a signal,
ircluding but not limited to fluorescers, :adiolabels, enzymes,
cremiluminescers r
or photosensitizers. Thus, binding may be
detected and/or measured by detecting fluorescence or
leinescence, radioactivity, enzyme activity or light ance.
Detectable labels may be ed to antibodies for use in the
irvention using conventional chemistry known in the art.
Trere are us methods by which the label can produce a
signal detectable by external means, for example, by visual
examination, electromagnetic radiation, heat, and chemical
reagents. The label can also be bound to another specific
g member that binds the antibody for use in the invention,
or to a support.
Labelled specific binding members, e.g. scFv labelled with a
detectable label, may be used stically in vivo, ex vivo or
in vitro, and/or therapeutically.
For example, radiolabelled binding members (e.g. binding members
conjugated to a radioisotope) may be used in radiodiagnosis and
radiotherapy. sotopes which may be conjugated to a g
member for
use in the invention e isotopes such as TC,
99mTC, 186Re, 188Re, 2O3Pb, 67Ga, 68Ga, 47SC, 1111,], 97Ru, 62Cu, 64Cu, 86y,
88 90 121 161 153 166 105 177 123 124 125 131 18
Y, Y, Sn, Tb, Sm, Ho, Rh, lu, I, I, I, I, F,
211At and 225Ac. Preferably, positron emitters, such as 18F and 1241,
99m 111
or gamma emitters, such as Tc, In and 1231
, are used for
diagnostic applications (e.g. for PET), while beta—emitters, such
{ii 131I, 90Y and 177Lu, are ably used for therapeutic
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
applications. Alpha—emitters, such as 211At and 225Ac may also be
used for therapy.
For example, a specific binding member for use in the invention
labelled with a detectable label may be used to detect, diagnose
or r 13D in a human or animal.
A specific binding member of the present invention may be used
for the manufacture of a diagnostic product for use in diagnosing
13D.
A conjugate or fusion between a g member for Jse in the
invention and a le that exerts a biocidal, cytotoxic
immunosuppressive or nflammatory effect on target cells in
the lesions and an antibody directed t an extracellular
matrix component which is present in such lesions may be employed
in the present invention. For example, the conjugated molecule
may be interleukin—10. Such conjugates may be used
therapeutically, e.g. for treatment of 13D as referred to herein.
Production and use of s or conjugates of specific binding
members with biocidal or cytotoxic molecales is described for
example in WOOl/62298.
The specific binding member for use in the invention may be a
conjugate of (i) a molecule which exerts an anti—inflammatory
effect on target cells by cellular interaction, an anti—
inflammatory molecule, a cytokine e.g. nd (ii) a specific
binding member for the ED—A isoform of fibronectin and/or the ED—
A of fibronectin.
The specific binding member for use in the ion may be a
coangate of (i) a molecule which exerts an immunosuppressive or
anti—inflammatory effect and (ii) a specific binding member for
the ED—A isoform of fibronectin and/or the ED—A of fibronectin.
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
The specific binding member for Jse in the invention is
preferably a conjugate of (i) interleukin—10 (ILlO) and (ii) a
specific binding member for the ED—A isoform of fibronectin
and/or the ED—A of fibronectin. Such a specific binding member
is usele in s of the invention disclosed herein relating
to treatment of 13D.
Also described herein is a conjugate of (i) a molecule which
exerts a biocidal or xic effect on target cells by ar
interaction, or an immunosuppressive or anti—inflammatory
effect and (ii) a binding member for the ED—A isoform of
fibronectin and/or the ED—A of fibronectin. Such a conjugate
preferably comprises a fusion protein comprising the biocidal,
cytotoxic, suppressive or anti—inflammatory molecule and a
said binding member, or, where the binding member is two—chain or
multi—chain, a fusion protein comprising the biocidal, xic,
immunosuppressive or anti—inflammatory molecule and a polypeptide
chain component of said binding member. Preferably the binding
member is a single—chain polypeptide, e.g. a single—chain
antibody le, such as scFv.
A conjugate, as referred to , may be expressed as a fusion
n. Thus, a fusion protein comprising the immunosuppressive
or anti—inflammatory molecule and a single—chain Fv antibody
molecule may be used in the invention.
The immunostpressive or anti—in lammatory molecule that exerts
its effect on target cells by ce"ular interaction, may interact
ly wish the carget cells, may interact with a membrane—
bound receptor on the target cell or perturb the electrochemical
potential of th c ll m mbran . Pr f :ably, the molecule is IL—
Preferably, the molecule which is conjugated to the specific
binding member is IL—lO.
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
As discussed further below, the specific binding member for use
in the invention is preferably an antibody molecule or comprises
an antibody antigen—binding site. Conveniently, the specific
binding member may be a sing'e—chain ptide, such as a
single—chain antibody. This allows for convenient production of
a fusion protein comprising single—chain antibody and, for
example, immunosuppressive or anti—inflammatory molecule (e.g.
interleukin—10 or TGF beta). An antibody antigen—binding site
may be provided by means of association of an antibody VH domain
and an antibody VL domain in separate ptides, e.g. in a
te dy or in an antibody fragment such as Fab or
diabody. Where the specific binding member is a two—chain or
multi—chain le (e.g. Fab 0: whole antibody, respectively),
an immunosuppressive or anti—inflammatory molecule, for example,
may be conjugated as a fusion polypeptide with one or more
polypeptide chains in the specific binding member.
The specific binding member may be conjugated with the
immunosuppressive or anti—inflammatory molecule by means of a
peptide bond, i.e. within a fusion polypeptide comprising said
molecule and the specific binding member or a polypeptide chain
component thereof (see e.g. Trachsel et al.). Other means for
coangation include chemical conjugation, especially cross—
linking using a bifunctional reagent (e.g. employing DOURL?—
95 RfiAGfiNTSTM Cross—linking Reagents Selection Guide, ).
Also provided is an isolated nucleic acid ng a specific
binding member for use in the present invention. Nucleic acid
may e DNA and/or RNA. A nucleic acid may code for a CDR or
set of CDRs or VH domain or VL domain or antibody antigen—binding
site or antibody le, e.g. scFv or IgG, e.g. IgGl, as
defined abov . Th nucl Otid s qu nc s may encode the VB and/or
VL domains disclosed herein.
Furth r d scrib d h r in ar constructs in the form of plasmids,
{:iCCOIS, transcription or expression cassettes which comprise at
ast one polynucleotide as described above.
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
A recombinant host cell that comprises one or more constructs as
above are also provided. A nucleic acid encoding any CDR or set
of CDRs or VH domain or VL domain or antibody antigen—binding
site or antibody le, e.g. scFv or IgGl or IgG4 as provided,
is described, as is a method of production of the encoded
product, which method comprises expression from ng nucleic
acid. Expression may conveniently be achieved by culturing under
appropriate conditions recombinant host cells ning the
nucleic acid. Following produCtion by expression a VB or VL
domain, or specific g member may be isolated and/or
purified using any suitable technique, then used as appropriate.
A nucleic acid may comprise DNA or RNA and may be wholly or
partially synthetic. Reference to a nucl Otid s qu no as s t
out herein encompasses a DNA molecule with the specified
sequence, and encompasses a RNA le with the ied
sequence in which U is substituted for T, unless context requires
otherwise.
A method of production of an antibody VH variable domain, the
method including causing expression from encoding c acid is
also described. Such a method may comprise culturing host cells
under conditions for production of said antibody VH variable
domain.
A method of production may comprise a step of isolation and/or
purification of the produCt. A method of production may comprise
formJlating the product into a composition including at least one
additional component, such as a pharmaceutically acceptable
excipient.
Systems for cloning and expression of a polypeptide in a variety
of different host cells are we" known. Suitable host cells
include baCteria, mammalian ce"s, plant cells, filamentous
, yeast and baculovirus systems and transgenic plants and
imals. The expression of antibodies and antibody fragments in
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
prokaryotic cells is well established in the art. For a review,
see for example Pluckthun (1991), Bio/Technology 9: 545—551. A
common bacterial host is E.coli.
Expression in eukaryotic cells in culture is also available to
those d in the art as an option for production of a
specific binding member for example Chadd
et al. (2001), Current Opinion in Biotechnology 12: 188—194
); Andersen et al. (2002) t n in 3i0technology 13:
117; Larrick & Thomas (200l) Current Opinion in Biotechnology
12:411—418. Mammalian cell lines available in the art for
expression of a heterologous polypeptide include e hamster
ovary (CHO) cells, HeLa cells, baby hamster kidney cells, NSO
mouse melanoma cells, Y32/0 rat myeloma cells, human embryonic
kidney cells, human embryonic retina cells and many others.
Suitable vectors can be chosen or constructed, containing
appropriate regulatory sequences, including promoter sequences,
terminator sequences, polyadenylation sequences, enhancer
seqiences, marker genes and other sequences as appropriate.
VeCtors may be ds e.g. phagemid, or viral e.g. 'phage, as
appropriate. For further details see, for example, Sambrook &
Russell (2001) Molecular Cloning: a Laboratory Manual: 3rd
edition, Cold Spring Harbor naboratory Press. Many known
techniques and prOtocols for manipilation of nucleic acid, for
example in preparation of c acid constructs, mutagenesis,
sequencing, introdJction of DNA into cells and gene sion,
and analysis of proteins, are described in detail in Ausubel
et al. (1999) 4th eds., Short Protocols in Melecular Biology: A
Compendium of Methods from t Protocols in Molecular
Biology, John Wiley & Sons.
A host ce" may contain a nucleic acid as described . Such
a host ce" may be in Vitro and may be in culture. Such a host
cell may be in vivo. In vivo presence of the host cell may allow
'dtracellular expression of a binding member for use in the
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
ed set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
t invention as “intrabodies” or intracellular antibodies.
Intrabodies may be used for gene therapy.
A method comprising introducing a nucleic acid disclosed herein
into a host cell is also described. I-The introduCtion may employ
any available technique. For eukaryotic cells, sJitable
techniques may include calcium phosphate transfeCtion, DfiAfi—
Dextran, electcoporation, liposome—mediated transfection and
transduction using retrovirus or o:her virus, e.g. vaccinia or,
for insect cells, baculovirus. Introducing nucleic acid in the
host ce", in particular a eukaryOtic cell may use a viral or a
plasmid based . The plasmid system may be maintained
episoma"y or may be incorporated into the host cell or into an
artificial chromosome. Incorporation may be eithe: by random or
targeted integration of one or more copies at single or multiple
loci. For bacterial cells, suitable technques may include
calcium chloride transformation, e:_eCtroporation and transfection
using baCteriophage.
The introduction may be followed by g or ng
expression from the nucleic acid, e.g. by culturing host cells
under ions for expression of the gene. The cation of
the expressed product may be achieved by methods known to one of
skill in the art.
The nucleic acid may be ated into the genome (e.g.
chromosome) of the host cell. Integ :ation may be promOted by
inclusion of sequences that promo :e recombination with the
genome, in accordance with standa :d techniques.
A method that comprises using a uct as stated above in an
expression system in order to s a specific binding member
or polypeptide as above is also desc :ibed.
Specific g members for use in the present invention are
{fisigned to be used in methods of diagnosis or treatment in human
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
ation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
ed set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
or animal subjects, e.g. human. Specific binding members for use
in the invention may be used in sis or treatment of 13D.
ingly, the invention provides methods of treatment
comprising administration of a specific binding member as
described, pharmaceutical compositions comprising such a specific
g , and use of such a specific binding member in the
cture of a medicament for administration, for example in a
method of making a medicament or pharmaceutical composition
comprising formulating the specific binding membe : with a
pharmaceutically acceptable excipient. Pharmaceutically
acc ptabl v hic S ar w ll known and will be adapted by the
person d i n the art as a function of the nature and of the
mode of st :ation of the active compound(s) chosen.
Specific binding members for use in the present invention will
y be administered in the form of a pharmaceutical
composition, which may comprise at least one component in
addition to the specific binding member. Thus, pharmaceutical
compositions described herein, and for use in accordance with the
present invention, may comprise, in addition to aCtive
irgredient, a pharmaceutically acceptable excipient, carrier,
bLffer, s tabilizer o : Other materials well known to those skilled
ir the art. Such materials should be non—toxic and should not
irterfere with the e Eficacy of the active ingredient. The
precise nature 0 f he carrier or other material will depend on
tre route of administration, which may be oral, inhaled or by
irjection, e.g. intravenous.
Ptarmaceutical compositions for oral administration such as for
example nanobodies etc are also envisaged in the present
irvention. Such oral formulations may be in tablet, capsule,
powder, liquid or semi—solid form. A tablet may comprise a solid
carrier such as gelatin 0 : an adjuvant. Lquid pharmaceutical
compositions generally comprise a liquid ca: :ier such as water,
{fitroleum, animal or vegetable oils, minera' oil or tic
l. logical saline solution, dextrose or other saccharide
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
solution or glycols such as ethylene glycol, propylene glycol or
polyethylene glycol may be included.
For intravenous injection, or injection at the site of
affliCtion, the aCtive ingredient will be in the form of a
pa:enterally accep':able aqueous solution which is pyrogen—free
and has suitable pi, isotonicity and stability. rThose of
relevant skill in the ar t are well able to p:epare suitable
solutions using, for example, isotonic vehicles such as Sodium
Chloride Injection, Ringer's Injection, uactated Ringer's
Injection. Preservatives, izers, s, antioxidants
and/or Other additives may be employed, as required. Many
methods for the ation of pharmaceutical formulations are
known to those skilled in the art. See e.g. on
ed., Sustained and Controlled Release Drug Delivery Systems,
Marcel De<ker, Inc., New York, 1978.
A composition may be administered alone or in combination with
other treatmen ts, concurrently or tially or as a combined
preparation wi th another therapeutic agent or agents, dependent
upon the condi tion to be treated.
A specific binding member for use in the present ion may be
used as part of a combination therapy in coannction with an
additional medicinal component. Combination treatments may be
used to provide significant synergistic effeCts, particularly the
combination of a specific binding member for Jse in the present
invention with one or more Other drugs. A specific binding
member for use in the present invention may be administered
concurrently or tially or as a combined preparation with
r therapeutic agent or agents, for the treatment of one or
more of the conditions listed herein.
For example, a specific binding member for use in the invention
may be used in combination with an existing therapeutic agent for
fie treatment of 13D.
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
A specific binding member for use in the invention and one or
more of the above onal medicinal componen :s may be used in
the manufacture 0 f a medicament. The medicament may be for
separate or combined administration to an dual, and
accordingly may se the specific binding member and the
additional component asa combined preparation or as separate
preparations. Sepa :ate p :eparations may be used 'ZO facilitate
separate and sequential o : simultaneous administration, and allow
administration of the components by different rou :es e.g. oral
and parenteral administration.
In accordance with the present invention, compositions p :ovided
may be administered to mammals. Administration may be in a
"therape Jtically ef fective amount", this being su Eficient to show
benefit to a patient. Such benefit may be at least amelioration
of at least one symptom. Thus “treatment of 13D" refers to
amelioration of a o least one m. The aCCJal amount
administered, and rate and time—course of administration, will
depend on the nat are and severity of what is being d, the
particular mammal being treated, the clinical ion of the
individual patien “I the cause of the disorder, the site of
delivery of the composition, the type of specific binding ,
the method of administration, the scheduling of administration
and other factors known to l practitioners. Prescription
of treatment, e.g. decisions on dosage etc, is within the
responsibility of general p :actitioners and other medical
dOCtors, and may depend on the severity of the symptoms and/or
progression of a disease being treated. Appropriate doses of
antibody are well known in the art (Ledermann et al . (1991) Int.
J. Cancer 47: 659 —664; and 3agshawe et al. (1991) Antibody,
Immunoconjugates and Radiopharmaceuticals 4: 915—922). Specific
dosages indicated herein, or in the Physician's Desk nce
(2003) as appropriate for th :yp of m dicam nt b ing
stered, may be used. A therapeutically effective amount or
suitable dose of a ic binding member for use in the
dvention can be determined by comparing its in vitro activity
d in Vivo activity in an animal model. Methods for
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
ed set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
extrapolation of effective dosages in mice and other test animals
to humans known. r
are The precise dose wilj_ depend upon a numbe-
of faCtors, including whether the antibody is for diagnosis,
tion or for treatmen “I the size and on of the area
b tr at d, th pr cis nature of the antibody (e.g. whole
dy, fragment or diabody), and the nature of any detectable
label 0 : other molecule a cached to the an tibody. A typical
artibody dose will be in the range 100 ug to l g for ic
applications, and 1 ug to 1 mg for topical applications. An
iritial higher loading dose, ed by one 0 : more lower doses,
may be stered. An antibody may be a whole antibody, e.g.
tr e IgGl r
or IgG4 isotype. This is a dose for a single ent
of an adult patien “I which may be proportionally adj Jsted for
crild :en and infants, and also adjusted f or other antibody
formats in proportion to moi_ecular weight. Treatments may be
repeated at daily, twice—weekly, weekly or monthly als, at
the discretion of the physician. T :eatments may be every cWO cO
four weeks for subcutaneous administra tion and every four to
eight weeks for intravenous administration. In some embodiments
of the present invention, treatment is ic, and the period
between administra :ions is about two weeks or more, e .g. about
three weeks or more, about four weeks or more, or aboaC once a
month. In other embodiments of the ion, treatment may be
given before, and/or after surgery, and may be administered or
applied directly at the anatomical site of surgical treatment.
Inflammatory Rowe' Disease (I 3D)
Inflammatory Rowe' Disease is a group of inf:_ammatory conditions
that affect the colon and sma" intestine. The major types of
I'3D are Crohn’s disease (CD) and ulcerative colitis (UC), while
Other types of I3D include co' 'agenous colitis, lymphocytic
colitis, ischaemic colitis, diversion colitis, Rehcet’s disease
and indeterminate colitis. CD can affect any part of the
gastrointestinal tract, whereas UC is typically restricted to the
nlon and rectum.
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
ed set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
13D, as referred to herein, may be CD, UC, collagenous s,
lymphocytic colitis, ischaemic colitis, diversion colitis,
3ehcet’s disease or indeterminate s. In particular, the
terms CD, UC, collagenoas colitis, lymphocytic colitis, ischaemic
co'itis, diversion co'i tis, Rehcet’ s disease and rminate
colitis, as used , may refer to aCtive CD, aCtive UC,
active collagenous coli tis, aCtive lymphocytic s, active
ischaeH ic colitis, active divefsion colitis, active 3ehcet’s
disease and ac:ive indeterminate colitis, respectively. In one
embodin ent, the I3D may be CD or UC. In ano:her embodiment, the
I3D may be CD I collagenous colitis, lymphocytic colitis,
ischaeH ic colitis, diversion colitis, Rehcet’s disease or
indeterminate colitis. In a further embodiment, the IBD is not
UC. Tr e I3 3 may be an I3D which is no: typically rest :icted to
inflamn ation in the colon and the rect am, such as CD. The I3D
may be an I3D which does nOt affect only the lining of the colon.
In a preferred embodiment, the IBD is CD. Most preferably, the
I3D is active CD.
FJIther aspects and embodiments of the invention will be apparent
to those skilled in the art given the present disclosure
ing the following experimental exempli fication.
All documents mentioned in this specification are orated
herein by reference in their entirety.
“and/or" where used herein is to be taken as specific disclosure
of each of the two specified features or components with or
without the other. For example “A and/or 3" is to be taken as
specific disclosure of each of (i) A, (ii) 3 and (iii) A and 3,
just as if each is set ou : individually herein.
Unless contex t dictat s o ,h rwis , th d scriptions and
tions 0 E the features set out above are not limited to any
articular aspect or men t of ,he invention and apply
ually to all aspects and embodiments which are described.
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
Certain aspects and embodiments of the invention will now be
illustrated by way of example and with reference to the figures
described above.
EXPERIMENTAL
MATERIALS AND S
Mouse IBD model
Mouse models for 13D which involve the administration of DSS are
known in the art. A suitable mouse model is also described, for
example, in OkayasJ et al. (1990), Gastroenterology, 98, 694—702.
For :h xp rim nts d scrib d h r in, colitis was induced in
6 mice (Jackson Laboratories, Bar Harbor, ME) by inclusion
of 3% dextran sodium sulfate (DSS) ( P 3ioMedicals) into drinking
water for 7 days followed by 3—5 days of normal drinking water.
Control mice were given standard water throughout the course of
the study. Mice were monitored for disease induction/progression
as evidenced by hemoccult on days 3—5 as well as by daily weight
change. Mice were euthanized at various times 3—5 days ing
cessation of DSS in the water to evaluate targeting, localization
and pharmacological effects of F8—IL—10
/IL10 radioiodination, purification, characterization and
dosing solution preparation
125I—F8/IL10 was prepared using Succinimidyl—iodobenzoate (SIB)
(Zalutsky & Narula (1988) Cancer Research, 48,1446—1450; ZalLtsky
& Narula (1987) Appl. Radiat. Isot. 38, 1051—1055; Cheng, et al.
(2002) J} Med. Chem. 45, 3048—3056). 3riefly, an aliquot of
Iodine-125 (20 uL ~2.0 mCi) (Perkin ?'mer, Waltham, MA) was
reacted with 2.5 ug N—Succinimidyl—3—(:ri—n—butylstannyl)
benzoate MMSn; MW = 508.23, synthesized by Texas
Biochemicals, Inc. e Station, TX) together with 10 ug NCS
{:ligma—Aldrich, St. Louis, MO) as an oxidant in 50 uL of methanol
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
containing 1.5% acetic acid (v:v) (both from Sigma—Aldrich).
After 15 min incubation at ambi nt t mp ratur th r maining
oxidant in reaCtion solu :ion was quenched by adding 10 ug sodium
bisulfate (reducing agent) (Sigma—Aldrich) and incubating at
ambien for
an additional min. temperature 5 The I—labe'ed SI?
was coangated to the F8—IL10 antibody (N 0.2 mg, wi ch a starting
molar :atio of approximately 2.5 :l for intermedia ,e to antibody)
by incabating at t tempe :a' t p 4 8.0. The
radiolabeled product (1”I—F8/L110) was purified using a pre—
balanced PD—lO column (G*JA Healthcare, Little Chal Eon I
ghamshire, UK) (poten wial non—speci Eic protein binding
sites on the column were sa:urated using bovine serum albumin,
followed by rinsing the colJmn with at I_east three column volumes
of PES), eluted in PES. A radiochemical yield of imately
30% was ed.
The radiochemical purity (RCP) and bioactivity of 125I—F8/IL10
were characterized via size ion chromatogram ( SEC), and
EDA-a Efinity column, :espectively. For SEC is,
approximately 1 uCi o 8/IL10 produc: solution was injeCted
in,o ,he HPLC (Agilen 1100, equipped with an in—line radioaCtive
detector) equipped wi :h a size exclusion column (G3000Sle, TOSOH
ences, Tokyo, Japan) and eluted with a flow rate of l mE
pe : minute with mobile solvent 0: 25 mM phosphate buffer, 0.15 M
VaCl, pH 6.8. The identity of H51-F8/IE "0 was confirmed by
ing i:s retention time in :adiomet :ic chromatogram to that
of the refe :ence F8/IL10 in UV (280 nm) chromatogram. An QCP of
greater than 99% was obtained for 125I—F8/IL10, with a radioactive
ic ac:ivity of approximate:_y 4.5 mCi/mg.
The bioactivity of 125I—F8—IL10 was determined via an EDA affinity
column assay. 3riefly, an aliquot (approximately 1 uCi) of ”51—
F8/I E10 was loaded on a pre—balanced EDA affinity col Jmn
(containing 250uL of EDA resin, the pre—balance was conducted by
bloc <ing the ecific binding sites with 9 mL 58A, 9 mg/mL in
as, and then by washing the column with 8 mL PBS). The affinity
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
column was washed with 6 mL of RSA (9 mg/mL in P58) and the
eluate was fractionally collected. The radioactivity in the
collected eluate and ing on the af finity column was
measured in a gamma counter. The percen :age of radioactivity
retained in the EDA—resin column out of total loaded
radioactivity was ated. A percentage of 64% of
radioactivity ed in the affinity column was obtained for
125I—F8/IL10.
The dosing solutions used for PK and tissue distribution studies
were prepared by mixing 125I—F8/IT.10 with un'abe'ed F8/IL10
(F8/ILlO stock solution), and a:ion buffer to the required
final concentration. The test article solution was prepared on
the day of dosing and t to ambient temperature prior to
administration to the animals.
M51-F8/IL10 biodistribution and localization to colon in IBD
mouse model
Untreated or DSS—treated mice were both treated with pOtassium
iodide (KI) water (20 mM) approximately 2~4 days prior to ,he
dosing (day 5—7 following initiation of DSS) to block the thyroid
uptake of any potertial unbound free I—l25 generated in vivo. On
day 9 following initiation of DSS treatment, a single dose of
125I—F8/IL10 was administered intravenor sly (IV). The dose and
radioactivity per group is outlined below:
i) Gro,p 0 — approximate dose per momse: 5 mg/kg
Group 0 — approximate radioactivity per mouse: 7.5 “Ci
(specific activity 75 uCi/mg).
ii) Gro,p l — approximate dose per momse: 5 mg/kg
Group 1 — approximate ctivity per mouse: 10 pCi
(specific activity 100 JCi/mg).
iii) Gro,p 2 — approximate doses per mouse: 0.15 mg/kg,
Group 2 — approximate radioactivity per mouse: 12 pCi
(specific ty 4490 LCi/mg).
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
ation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
Subgroups of mice were bled at 5 s, l, 3, 6, 24, 48 and 96
hours and then various tissues were collected. Blood samples
were colleCted either by cardiac punc :ure or retro—orbital
bleeding into serum separator colleCtion tubes. Serum samples
were harvested by fugation of the blood samples at 10,000 g
for 5 min. For tissue collection, the animal was sacri ficed and
tissues of int r st w r coll ct d imm diat ly after blood
sampling and whole body per fusion. The whole body blood
perfusion was condJcted by administering approximately 20 mL of
heparin—P38 (25 units per m.J for approximately 10 min. The
s of interest included brain, mesente ric lymph nodes, skin,
fat, skeletal thigh muscle, lung, heart, spleen, liver, stomach,
small intestine, large intestine, and kidney were collected and
weighed. The contents in GI were removed. The radioactivity
(total counts in cpm) of the tissue samples was measured directly
by gamma coanter.
Colon autoradiography of diseased and healthy mice
Colon autography was performed on colons from Group 0 and
Group 2 mice. Colons were ted, their contents removed, and
tissue was exposed to a phosphor—imaging screen (Molecular
Dynamics) for 24 hours , and imaged via 3:orm 860. The results
are shown in Figure 2. sane—l: colon harvested at 6—hr post
injection from Group 0 (healthy ; sane—2: colon harvested
at 6—hr post injection from Group 2 (DSS treated mouse); Lane—3:
colon harvested at 24—hr post injection from Group 0 (healthy
mouse); Lane—4: colon harves:ed at 24—hr post injection Group 2
(DSS treated mouse). Patchy localization of 125I—F8/IL10 was
ed along the colon in the DSS treated mice and nOt in the
normal mice, consistent with the irregular colonic inflammation
and associated expression profile of the target EDA in this
model.
Determination of radioactive equivalent concentrations in serum
and tissues and pharmacokinetic calculations
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
The seer equivalent tration (ng eq./g) of 125I—F8/IL10 was
estimated based on the measured TCA loroacetic acid)
precipitable (protein associated) radioactivity. For TCA
itation, the t (50 ML) of serum sample was mixed with
50 “4 of mouse serum, followed by the addition of 100 ML of 20%
TCA SOlJCiOH. The sample miXture was spin at 10,000 g for 5
minuces to precipitate the protein. TOtal and TCA—soluble
radioaCtivity in the supernatant was determined. TCA—
precipitable radioaCtivity (cpm) in a given sample, the specific
ty of the do sing solution recipitable cpm per mg of
protein), as well as dates of sample (ts) and dosing solution
(tD) measurements, were used to calculate the equivalent
concentration of test article (ng eq./mL) in a given ,
using the formula: [TCA—precipitable cpm/EXP(—0.693/60.2*( ts —
td))]/[specific activity (in cpm/mg)*sample volume (in mL)].
The quantitation o f equivalent concentration (ng eq./g) of 125I—
F8/IL10 in tissues was calculated based on the measured total
radioactivity in the sample and the specific activity of the
dosing solution after a correCtion for physical decay half—life
of 125I, using the formula: [sample cpm/EXP(—0.693/60.2*(ts —
tD))]/[Specific activity (in cpm/mg)*sample weight (in mg)]. No
homogenization or TCA—precipitation was performed for tissue
samples. In addition to radioactive lent concentration (ng
eq./mL for serum, ne eq./g for ), percentage of injected
dose per gram (%ID /g) and/or percentage of injeCted dose (%ID)
were also ated for serum and tissues of interest.
3iodistribution o: 125I—F8/IL10 in normal (Group 0) and D88
treated (Group 1) mice was determined 6 hours (Figure 3A), 24
hours (Figure 33) and 96 hours post—injection (Figure 3C).
PK parameters were calculated with the mean serum or tissue
concentrations at the measured time points. A non—compartmental
analysis module of the pharmacokinetic software e WinNonlin
{:lersion 5.1, Pharsight) was used. The area under the
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
concentration versus time curve (AUC) was calculated using the
linear trapezoidal method.
Effect on serum ne levels with eutic treatment of F8-
ILlO in mouse model of IBD
As IL—10 is known to decrease proinflammatory cytokines, we
tested whether administration of F8—InlO in the mouse model of
I3D would affect serum cytokine responses in this model. Mice
were administered 200ug/mouse of F8—I410, or control small Immune
Protein (F8—SIP) IV on day 3, 6 and 9 following initiation of DSS
treatment (n=lO mice/group). This dose regimen was the same as
effective regimens in collagen induced arthritis models (Schwager
K, et al. Arthritis Research and Therapy, (2009) 11: R142).
Control groups included non—diseased (regular water) and
unt: at d dis as d (n—lOmic /group). On day 10 following
initiation of DSS, blood was collected and serum obtained as
described above for localization studies. Serum was evaluated
for levels of IL—lb, IL—12p40, IFNg, IL—6, KC, IL—lO and TNFa
using MSD technology platform and a mouse 7plex MSD kit according
to manufaCturer’s ctions (Mesoscale Discovery,
Gaithersburg, MD). Levels of cytokines are expressed as pg of
prOtein per ml of serum in Figures 4 and 5.
Human tissue ng for EDA sion
Immunohistochemical analysis of frozen OCT—embedded specimens of
colon tissue of a 60 years old female patient ed by
ulcerative colitis and of a 42 years old male patient ed by
Crohn’s disease. Both ens were probed with the F8 antibody
in SIP format and the Von rand factor.
In addition, affeCted and non—affeCted frozen biopsy specimens
paired from the same patients with Crohn’s or ulcerative s
(n=3 Crohn’s patients and n=5 UC patients) were obtained from
Analytical Riological Services (Wilmington, DE). Frozen samples
were orientated on dry ice to prevent thawing, embedded in
Dyomolds, standard (Tissue—Tek 4557) filled with O.C.T. compound
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
(Tissu —T k 1583) and flash frozen in isopentane that had been
cooled by dry ice. The tissue blocks were sectioned on a Leica
CMl850 cryostat at 4 microns, placed onto glass slides and stored
at —800C until the immunohistochemistry (THC) was performed.
Upon iniciacion of THC, tissues were dipped in cold (—20 F)
methanol (Fisher Scientific A412P—4) to remove any moisture that
can form wish scorage and air dried 20 min at room temperature.
Tissues were then dipped into cold (—20 F) acetone (ACROS CAS
67—64—1) for 10 min and air dried 10 min room temperature.
Tissu slid s w r lab l d with riate Ventana bar code and
placed into a a Discovery XT for Fibronectin F8 SIP or KSF
SIP ol antibody) THC. Endogenous biOtin was blocked with
both 5% Normal Mouse Serum (Jackson Immuno Research 015—000—120)
in a S 3lock(Ventana 760—4212) for 20 minutes and Ventana
RiOtin ng kit (Ventana 760—050) for 8 minutes. Fibronectin
F8SIP or KSF was diluted in Dako antibody diluent ) (Dako
worth America, Carpinteria, CA) at 1:200 concentration (100 ul
per slide) and incubated for 40 minutes. Slides were
counterstained with hematoxylin and bluing reagent (4 minutes
each) before the run was completed. Th slid s w r r mov d and
placed into a a Symphony for subsequent dehydration and
coverslipping. Representative images of THC are shown in Figure
7. THC from non—affected (left) and affected (right) tissue
samples from ulcerative colitis patient UH0501—34 (top)and
Crohn’s patient UH0405—09 m).
RESULTS
Colon autoradiography
Figure 2 shows autoradiography of colons of either non—diseased
mice (water) (lanes 1 and 3) or diseased mice (DSS—treated)
(lanes 2 and 4) at either 6 (lanes 1 and 2) or 24 (lanes 3 and 4)
hours following administration of radiolabeled F8—IulO. This
trates that the F8—IulO does accumulate in the inflamed
Dlon more so than the normal colon. The patchy appearance of
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
ation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
the diseased colon localization of the F8—ILlO is consistent with
the variab'e levels of inf' ammation and EDA expression observed
along the length of the colon in this model further supporting
zation of F8—Ith with the inflammation.
Biodistribution of -lLlO in diseased and healthy mice
Figure 3 shows the accumulation of the 125I—F8—IL10 at 6, 24 and
96 hour time points in the colon and mesenteric lymph nodes
(4.N.) in diseased (DSS) mice compared wi:h normal (water) mice.
Similar to Figure 2, these da:a demons trate the Large ting of F8—
1410 to the colon and associated lymph nodes in DSS—t :eated mice.
Also from these studies, the serum hal life was dete :mined to be
approximately 3.5 hou :s s the ha'f— 'ife of F8—Ith in the
colon was approximate:_y 35 hours; a lO—foj_d increase ting
enhanced tissue persistence. This indicates that not only is F8—
ILlO targeting the colon and mesenteric i_ymph nodes during
colonic inflamma :ion, but once there it a:_so persis:s for longer
periods of time than in circulat ion. Co" ectively these data
suggest tha: under ions of inflammation in the colon, such
as in Crohns disease and ulcerative colitis in , the F8—
ILlO will p :eferentially target and persist at these sites.
Cytokine levels in serum from diseased and healthy mice
Figure 4 shows that compared to control groups, the
administration of F8—ILlO in a therapeutic modality results in a
significant d cr as in s rum l v ls of inflamma tory cytokines,
IL—lB, IL12p40, IFNy and IL-6.
Figure 5 shows that compared to control groups, the
stration of F8—ILlO in a therapeutic modali:y does not
result in an increase of TNF—alpha and noci:e derived
chemokine (KC) and results in increased levels of I l—lO. The
increased levels of these cytokines of Figure 4 in the DSS model
are associated with the induction of the disease in the colon.
Dcreases in these inflammatory cytokines of Figure 4 and
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
ation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
increases in IL—lO are consistent with known biological effects
of IL—"O (Abbas A, Eichtman A, Pobe r J., 1994, Cellular and
Molecular logy. 2nd Ed. Philadelphia: W.3. Saunders
y; Delves P, Roitt I (edS), 1 998, Encyclopedia of
Immuno'ogy, 9nd Ed. San Diego: Academic Press). Thus, the F8—
ILlO demonstrates pharmacological activity in this model of I3D
by reducing cyto <ines associated with in flammation and pathology
in the IBD sett ing. Since these pro—inflammato :y cyto<ines are
known to be upregula :ed in IBD patients, downregulation of these
cytokines throagh administration of F8—I E10 suggests that F8—ILlO
is likely to be bene Eicial in treating I3D in Vivo. Interferon y
and IL—12p70, in par icular, are known to be upregulated in CD
patients, and the data disclosed herein suggest that
stration of F8—ILlO is therefore likely to be particularly
useful for treating CD in vivo.
Immunohistochemistry
Figure 6 shows that that the F8 SIP antibody stains the newly formed
blood vessels but not the normal blood vessels in a t affected by
ulcerative colitis. (Von Willebrand factor is routinely used as a
marker of normal vasculature.)
Figure 7 shows representative images of s or UC paired
biopsy samples stained by immunohistochemistry for I‘
.4 DA. Arrows
ir dicate vessels within each image. The intensity of staining
around s in the ed vessels is increased compared :0
Jraffected samples from the same patients. This suggests tha
:r -—I
e increased EDA exp n could result in increased targeting
to inflamed areas 0 the colon in these human disease settings.
Ir summary, the colo ted dis tribution and decreased serum
cytokines observed with F8— E10 in a murine I3D model as well as
t? e increased expression of EDA aroand vessels in affected human
Crohn’s and ulcerative colitis colon tissue collectively e
evidence that sugges: that administ :ation of F8—ILlO could target
and positively affec: patients with 13D.
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
ed set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
ation] kjm
ionNone set by kjm
[Annotation] kjm
Unmarked set by kjm
SfiQUfiNC*S DISCLOSED IN APPLICATION
SEQ ID WO:1 (F8 antibody VH domain CDRl)
SEQ ID NO:2 (F8 antibody VH domain CDR2)
SGSGGS
SEQ ID NO:3 (F8 antibody VH domain CDR3)
STHLYL
SEQ ID NO:4 (F8 antibody VL domain CDRl)
MPF
SEQ ID NO:5 (F8 antibody VL domain CDR2)
GASSRAT
SEQ ID NO:6 (F8 antibody VL domain CDR3)
MRGRPP
SEQ ID NO:7 (F8 antibody VH )
fiVQLLfiSGGGLVQPGGSLQLSCAASGFTFSLFTMSWVRQAPGKGL EWVSAISGSGGSTYYADSVK
GQFTISRDNSKNTLYLQMVSLRA EDTAVYYCAKSTHLYLFDYWGQGTLVTVSS
SEQ ID NO:8 (F8 an :ibody VL domain)
EIVLTQSPGT1T.SISPGERATLSCRASQSVSMPFLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG
SGSGTDFTLT1IS'RT.*1]?*iDFAVYYCQQMRGRPPTFGQGTKV EIK
SEQ ID NO:9 (lin<er between VH domain and VL domain of F8
antibody)
GGSGG
SEQ ID NO:10 (Linker between VL domain of F8 antibody and IL—10)
dSSGSSSSGSSSSG
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
[Annotation] kjm
Unmarked set by kjm
[Annotation] kjm
None set by kjm
[Annotation] kjm
MigrationNone set by kjm
ation] kjm
ed set by kjm
S3Q ID NO:ll (h Jman IL—lO)
SPGQGTQSL‘JVSCTHFPGNLPVMLRDLRDAFSRVKT1FFQMKDQTDNT. .LK fiSLLfiDE {GYLGCQAL
S fl IQEY.fi fiV PQA fiNQDP DIKAHVNS .G3NLKTLRLRLRRCHRF ?NKS<AV EQVKNAFNK
LQ EKGIY {A SjEDIEINYIiAYMTMKIQN
3 W0: 12 (F8 antibody)
mfiSGGG .VQPGGSLR 4SCAASGFTFSLFTMSWVRQAPGKGLEWVSAISGSGGSTYYADSVK
FTIS DNS {NT .YLQMNS .RA YCAKSTHLYJFDYWGQGTJVTVSSGGSGGEIVLTQS
GT4 a :RAT" .SCRASQSVS PFLAWYQQKPGQAPQLLIYGASSRAT1GIPDRFSGSGSGT‘DF
1DEAVYYCQQMQGRPPTFGQGTKVEIK
ID W0: l3 (F8—I 410)
.VQPGGSLRLSCAASGFTFSLFTMSWVRQAPGKGL EWVSAISGSGGSTYYADSVK
{NT .YLQMVS .RA 3DTAVYYCA {ST {LYJFDYWGQGTJVTVSSGGSGGEIVLTQS
RAT" .SCRASQSVS PFJAWYQQ QJLIYGASSRATGIP DRFSGSGSGTDF
YCQQMQG RPPTFGQGTKV SSGSSSSGSSSSGSPGQGTQSL‘JWSCTH
DLR DAFSRVKTFFQMK DQLDNL ..K1 .fiDE {GYLGCQALSIJ. IQEYLfifiV PQ
{VNS .GQNLKTLQLRL'RRCHRF {AVjQVKNAENKLQjKGIYKA SEFD
TMKIRN
Claims (13)
1. Use of an antibody ate for the preparation of a medicament for the treatment of inflammatory bowel disease (IBD), wherein the antibody conjugate comprises an antibody, or an antigen-binding fragment f, that binds the Extra Domain-A (ED-A) of ectin and is conjugated to an immunosuppressive or antiinflammatory molecule, said dy comprising a VH domain and a VL domain, n the VH domain comprises heavy chain CDR1, CDR2 and CDR3 amino acid sequences comprising the amino acid sequences of SEQ ID NOs: 1, 2 and 3, respectively; and the VL domain comprises light chain CDR1, CDR2 and CDR3 amino acid sequences comprising the amino acid sequences of SEQ ID NOs: 4, 5 and 6, respectively.
2. Use of an antibody ate for the preparation of a medicament for the delivery of an immunosuppressive or anti-inflammatory molecule to sites of matory bowel disease (IBD) in a patient, wherein the antibody conjugate comprises an antibody, or an antigen-binding fragment thereof, that binds the Extra Domain-A (ED-A) of fibronectin and is conjugated to the immunosuppressive or anti-inflammatory molecule, said antibody comprising a VH domain and a VL domain, wherein the VH domain comprises heavy chain CDR1, CDR2 and CDR3 amino acid sequences comprising the amino acid sequences of SEQ ID NOs: 1, 2 and 3, respectively; and the VL domain comprises light chain CDR1, CDR2 and CDR3 amino acid sequences comprising the amino acid sequences of SEQ ID NOs: 4, 5 and 6, respectively.
3. The use according to claim 1 or 2, wherein the VH domain and/or the VL domain comprises a human germline ork.
4. The use according to claim 3, wherein the human germline framework in the VH domain is from a human DP47 gene and/or the human germline framework in the VL domain is from a human DPK22 gene.
5. The use according to claim 1 or 2, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 7; and the VL domain comprising the amino acid sequence of SEQ ID NO: 8.
6. The use according to any one of claims 1-5, wherein said antibody or antigenbinding fragment is ated to a detectable label.
7. The use according to claim 6, wherein the detectable label is a radioisotope.
8. The use according to any one of claims 1-7, wherein said anti-inflammatory molecule is a cytokine.
9. The use according to claim 8, n said cytokine is human interleukin-10 (IL-10).
10. The use ing to any one of claims 1-9, wherein said antibody or antigenbinding fragment is conjugated to said immunosuppressive or anti-inflammatory molecule by a cleavable linker.
11. The use according to any one of claims 1-9, wherein said antibody or antigenbinding fragment is conjugated to said immunosuppressive or nflammatory molecule via a peptide linker.
12. The use according to claim 11, wherein said peptide linker ses 15 amino acids. 13. The use according to claim 12, wherein said peptide linker consists of the amino acid residues (SSSSG)3 (SEQ ID NO: 10). 14. The use according to any one of claims 1-13, wherein the antibody conjugate comprises an antigen-binding fragment of said antibody. 15. The use according to claim 14, wherein said n-binding fragment comprises a small immunoprotein (SIP). 16. The use according to claim 14 or 15, wherein said antigen-binding fragment comprises a single chain Fv (scFv). 17. The use according to claim 16, wherein the VH domain and the VL domain in the scFv are conjugated to each other via an amino acid . 18. The use according to claim 17, n said amino acid linker comprises 5 to 25 amino acids. 19. The use according to claim 14 or 15, wherein said antigen-binding fragment is a diabody that comprises a polypeptide comprising the VH and VL domains, wherein the VH and VL domains in the polypeptide are conjugated to each other via an amino acid linker comprising 1-5 amino acids. 20. The use according to claim 19, wherein said amino acid linker consists of the amino acid residues GGSGG (SEQ ID NO: 9). 21. The use according to claim 20, wherein said antibody conjugate comprises (i) the diabody and (ii) human interleukin-10 (IL-10) conjugated to the VL domain of the diabody via a peptide linker comprising the amino acid residues (SSSSG)3 (SEQ ID NO: 10). 22. The use according to claim 20, wherein said antibody conjugate consists of (i) the diabody and (ii) human interleukin-10 (IL-10) conjugated to the VL domain of the diabody via a e linker consisting of the amino acid residues (SSSSG)3 (SEQ ID NO: 10). 23. Use of an antibody ate for the preparation of a medicament for the treatment of inflammatory bowel disease (IBD), wherein said antibody conjugate ses the amino acid sequence of SEQ ID NO: 13. 24. Use of an antibody ate for the preparation of a ment for the treatment of matory bowel disease (IBD), wherein said antibody conjugate consists of the amino acid sequence of SEQ ID NO: 13. 25. Use of an antibody conjugate for the preparation of a medicament for the delivery of human IL-10 to sites of inflammatory bowel disease (IBD) in a patient, n said antibody conjugate comprises the amino acid sequence of SEQ ID NO: 13. 26. Use of an antibody conjugate for the preparation of a medicament for the delivery of human IL-10 to sites of inflammatory bowel disease (IBD) in a patient, n said antibody conjugate consists of the amino acid sequence of SEQ ID NO: 13. 27. The use according to any one of the preceding , n said IBD is selected from any of the following: ulcerative colitis (UC), collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behcet’s disease, indeterminate colitis, and Crohn’s disease (CD). [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm ation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm .4“ 3...\ ...\\, xx.\x.« “in.\3 RW. 5“} «at. [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm ation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm ation] kjm Unmarked set by kjm ii .\§\ [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm ed set by kjm [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm [Annotation] kjm ionNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm é: , N \ .T P, (v i h.» »§\\\\\\\\\\~. “ w V“ ,. H h‘““ “ “ . ‘m Vsss~ss§ f V §flxx wx§ v & N “ssssh. n aw“ s“ ~ii okx. “zsks‘sxzkktti. ésssssssk SEEK a) “a ‘\\\\\\\\\\\\ »“ ~~ ~ m \x\ w. xx \, “x‘ “ “\ “1 m\ “‘ g\ Rm. rs. n. . RE: “‘ o. ‘ viV‘“ “x .m » tt\l\§ \xitxv§\{\\ Vsssgxi " k}: . \ witsiii S \«1 ‘ \ \ Egg (L “_ AK...“\“xxxw s“ “ “ “‘sz“\ n “ e!“ . ‘ \“ . ‘ w ,s\\\\m\\\~~\~§: w ‘ m. ” .J » v wm« w Hw it{:{§)X§\..{§\§t\§ ‘;\:\x{:\t _. M \ . . ‘ _, H :§{\\\t? .. M““x N. x‘“m mv . «\\\\\\\\‘\ . oxQx“ .. .AI..im. “I: . S. n4.“.xs\“A, a:C [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm Q \ x. it}! Q,. .. so» §§$§§§x .x3 3: Q Qu Q Q . Q b . , .Q. $\\\\\\\.\\.\\.\§\\\§\\w\§§\§xtto}?! QQQ m::.,.........:...,..,..:,.....§;...,..,, $§§x§§§~§§§§§ss QMQQ :35¢E>5:EQ§§>$§~§§§S~§§§S Q»: §\\\\\\\\\. QQ \ QQQ.‘C Qi\AQ. .. xii!) Q\ v\\\s\\\_\\§\\\\\\\\\\\x\\\. .S.§\\.\a§§\§\\§§\\§\§§\\§§\x§\§\x\\\. \:3\QQ\.Q .,\ “QM,.\ Q: \xxx\.«Q x \ Q 4 , Q Q $§mfix Q\ Q” 333% x Q x: HQ: Q Q 3% V Q. :QQ: .: .»,.»..\h:.\\Xfix Q Q: xxfi‘: . \Q Q :1}. ,.:.\,.x..\, \xfi» SSS. Q Q 3 fik§§3¢s Q ; Q\ Wv§$w xQ . :x‘ $33 e.) &.. :“33$ ttttt :§ Q .Qfifi \SESQQ Q. QQi, Q» Q. §, \ ..w&.. . VWNQ $.31 : ks: Az :3; « tits: Q:: 33:3: , i»?! .43»:}i§x Q: .\\\\ , QQQ m§9:, fl . . Sax: Qfi.m. {35$ Q: Q «x::3 \xii: xw.m:mQm QN W, 3 x \ xxxxmmxxQm\mQxWQQmummmQ WmQmmQQQQx\N§§§x§\\\\§\\\\i§§§i§x\§§< . Q \xvxxx\\:§§Q\Qt\x\§\\\\§\\\\\§§\\\\w§%\\\\§\§§%xxxxxxxcwxsuaexs§\§x§x§\\sfix§x§x\§§x§x«w , \, \« “cm? :2: x i\ Q : .RMQ .x. QQQ y .3 M \3 wfl: k»5. . Q . Q .x? x . Qx,w Q:x .3.\\ \\\\>, WMa“:Q?»Q:w: ‘93: . QNw ms; xxx), Q: SS: fix«R:Q«Q. \Q»QMQ3. xxx? Nk. : , 3Q+5As».E figfiN, Q1 .\\\§ NQQQ:
13.,“x.\. : : Q.\: : :\ . §§§xlw «xxx .. . :x 3. . Q Q 3125‘ i ~Y23§31§32§§§3 Q QNQQ Q v Q »Q Q . .. Q . Q , . Q, W33.WV: ow V .:\\\\\\\\Q.\.~\§§xxQ33 §%§\\§\\\§\V\$\\u§§§\\n\\\\$\%\{\\\S\\\\‘i\\§\\\\“\\\\\\\‘5‘\\\\\\\\\N§\\\.\\C§\\\\\\\\\X§§ ‘sx‘x «VQQQ u Q ..mw. Q . _. \ x Q Q \\\\\®\\§: . Q § . §§§§§QWkfi .x Qu .. a i \\\\\a Q \\\§\ QQQQ .. k“ _H\Q z$ m\W‘\\\\\\\\\ QQ X: Q w:xx,NQQx.Q.m.xQQQQQQQN\. NQQw.mQQN\Q\\QQQ.Q.x.§§N€“\\ «kQH «NW “Q\mQ:Q;xQQQQHmR“W. xQMm“Wm\Q w \: Q “x : \¢ . N \s xQ fix :x. Q»Q. {xc.Q: Q “AM“H3.“Q933 \x: .:Q: N‘\\ . »\ Q. x 3 \ s: [Annotation] kjm None set by kjm ation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm ”‘3.rw.T. xmw. 3, wk a» w:\ N“;N“. ‘35“.\ Six\\Wu.\x\ 3 3*. Q fifl i\\.\ .m?‘sezmmzis .& Q x3 a\\\3\\\\\\\\\\§\\\\\\\\\\\xxx.“x,AA§x\\\«3‘x\“Y\\\\\\§\\\\\\\\\\\§K\§\\N§§\\§§\s\\\\\\.\~\.\x Q fixwwmxw\\\\ um. .\\§EswxxxSStxx‘c\\\\v~\i§k§\§§\\\.§ x\\§ K mmNvmflsix$\\\\\\.\\\\& §.§ \{Em \S&“s |K\\\ mm $ :N\\\\N\\\\\~ N m:‘ ‘ \. \{nn SEEWEE; «i»? E .5: w \s, \\x§\ 5%»w .. \2xe3§. \.m.\§v\+ \; my mmwmxum. N3;NxhuigH\\\W\A?» v my . \C‘ {m\. kw “em«9&1: 3%\x \. .svyvvi‘xwkkrlv »\\\\\\\\..\.tN\\\\\\\\\\\x\\§\\\\xx{xxksfikt\xx\\\\x\\x\\\\\\x\\\n\\\\\\\\\\»\x\x\k\¢§x§§»§\s§§s~m\ \» & «\mwmwn% \§§\k\\.‘\\k\§\s Xv \ . ,w iii: W . (3&3: «N.8 “xxxoxv aw xi... «Xx xxxx§§x$X8» meam xK\\\\\\N\\\\X\A~\\\vY§\\\\\%§§\\\\\\\\\§\\\\\\x§ MW m;\w §. SNKi‘!«SSWSSS{N}. fifi ”\Sfiw\b:\8\ \« RNN xwm\3%. «W? §§§Nx§o §§x 9»xmé $fiwx§ mg» km a 8%: .\.<.. \wxW \ww w“um W.Nxn m . l m». ix \pi NV \¢\».« \63 \Kx'mkmxx»;«-a§x\\\\x\'x\\\\\\~<\'\'<<K mmmmwm \§§\\\\h\\\\§»\§\\§\\\\\\§\\\\3‘\\\§\\\x\¢\\x\\x\§Q\\\§\\\.\\\§\\\\\\\\(\§s§§§§§§§x§§\‘ xx t. {w . MK xx \9 $.83. x 3%.. .33 «3“.RV: $3 «\3. \oWW‘ D‘ .v \ ”an [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm ed set by kjm [Annotation] kjm None set by kjm ation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm -‘.‘ e“? \3; A ..\.“ In” -“ Wm: m r : ,shixm “s [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm ation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm [Annotation] kjm None set by kjm [Annotation] kjm MigrationNone set by kjm [Annotation] kjm Unmarked set by kjm \aV~\~~~\~\\~\\‘\\~\\~~\~~\~‘\‘V\u~\~~~~~»~~»~~~~~~\\‘\~\~\»\ \‘xitht.K ‘ \Ikxxlsxlit .353} ,. : {xxxtxt .31} \uiu. «u... “m“mxmN“w.“Mw“~“wv,“g~~\ s~ ”WM“kwfi.~“§\\w\u.u._mum“ \\ \\\\\\\\\\\\\ .. §§x«\\\\\\\\\\\\\\\\\\\ \... fifi x», \«x\&
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2012/058574 WO2014055073A1 (en) | 2012-10-03 | 2012-10-03 | Antigens associated with inflammatory bowel disease |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ631476A NZ631476A (en) | 2017-06-30 |
NZ631476B2 true NZ631476B2 (en) | 2017-10-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10239939B2 (en) | Anti-ED-A immunoconjugates for inflammatory bowel disease | |
US10112992B2 (en) | Antigens associated with endometriosis, psoriatic arthritis and psoriasis | |
ES2534726T3 (en) | ED-A fibrinogen antigen that is associated with lymphomas | |
ES2807753T3 (en) | An antigen associated with rheumatoid arthritis | |
EA036322B1 (en) | Novel antigen associated with the neovasculature of tumour metastases | |
JP2009268470A (en) | Selective targeting of tumor vasculature using antibody molecule | |
CA2468081A1 (en) | Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours | |
KR101129161B1 (en) | Targeting of Tumor Vasculature Using Radiolabelled Antibody L19 against Fibronectin ED-B | |
NZ631476B2 (en) | Antigens associated with inflammatory bowel disease | |
TWI499426B (en) | Antigens associated with inflammatory bowel disease | |
JP2017197558A (en) | Antigen associated with inflammatory bowel disease |